KR101814538B1 - A cosmentic composition comprising the bio-cellulose powder for reducing and preventing cellulite - Google Patents
A cosmentic composition comprising the bio-cellulose powder for reducing and preventing cellulite Download PDFInfo
- Publication number
- KR101814538B1 KR101814538B1 KR1020160048596A KR20160048596A KR101814538B1 KR 101814538 B1 KR101814538 B1 KR 101814538B1 KR 1020160048596 A KR1020160048596 A KR 1020160048596A KR 20160048596 A KR20160048596 A KR 20160048596A KR 101814538 B1 KR101814538 B1 KR 101814538B1
- Authority
- KR
- South Korea
- Prior art keywords
- cellulose
- bio
- cellulite
- acid
- microbial cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- 208000035484 Cellulite Diseases 0.000 title claims abstract description 45
- 206010049752 Peau d'orange Diseases 0.000 title claims abstract description 45
- 230000036232 cellulite Effects 0.000 title claims abstract description 41
- 230000003405 preventing effect Effects 0.000 title claims abstract description 13
- 230000001603 reducing effect Effects 0.000 title claims abstract description 12
- 229920002678 cellulose Polymers 0.000 claims abstract description 41
- 239000001913 cellulose Substances 0.000 claims abstract description 41
- 239000002537 cosmetic Substances 0.000 claims abstract description 39
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 229920001340 Microbial cellulose Polymers 0.000 claims description 57
- -1 body cleansers Substances 0.000 claims description 55
- 239000006210 lotion Substances 0.000 claims description 36
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 239000006071 cream Substances 0.000 claims description 24
- 238000009472 formulation Methods 0.000 claims description 22
- 244000005700 microbiome Species 0.000 claims description 22
- 239000003921 oil Substances 0.000 claims description 21
- 229930091371 Fructose Natural products 0.000 claims description 16
- 239000005715 Fructose Substances 0.000 claims description 16
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 239000013587 production medium Substances 0.000 claims description 13
- 230000003020 moisturizing effect Effects 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 235000020415 coconut juice Nutrition 0.000 claims description 9
- 235000016709 nutrition Nutrition 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000012535 impurity Substances 0.000 claims description 7
- 230000035764 nutrition Effects 0.000 claims description 7
- 239000012533 medium component Substances 0.000 claims description 6
- 238000003825 pressing Methods 0.000 claims description 6
- 239000000344 soap Substances 0.000 claims description 6
- 244000235858 Acetobacter xylinum Species 0.000 claims description 5
- 235000002837 Acetobacter xylinum Nutrition 0.000 claims description 5
- 239000006260 foam Substances 0.000 claims description 5
- 238000007654 immersion Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 239000008188 pellet Substances 0.000 claims description 5
- 244000283763 Acetobacter aceti Species 0.000 claims description 4
- 235000007847 Acetobacter aceti Nutrition 0.000 claims description 4
- 241000589212 Acetobacter pasteurianus Species 0.000 claims description 4
- 241000032686 Gluconacetobacter liquefaciens Species 0.000 claims description 4
- 241000589216 Komagataeibacter hansenii Species 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000008269 hand cream Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 19
- 230000009467 reduction Effects 0.000 abstract description 9
- 210000000689 upper leg Anatomy 0.000 abstract description 9
- 230000006872 improvement Effects 0.000 abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 7
- 210000004003 subcutaneous fat Anatomy 0.000 abstract description 7
- 230000002500 effect on skin Effects 0.000 abstract description 5
- 238000007665 sagging Methods 0.000 abstract description 5
- 238000009499 grossing Methods 0.000 abstract description 4
- 230000037394 skin elasticity Effects 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 235000019198 oils Nutrition 0.000 description 20
- 239000000843 powder Substances 0.000 description 17
- 235000014113 dietary fatty acids Nutrition 0.000 description 15
- 239000000194 fatty acid Substances 0.000 description 15
- 229930195729 fatty acid Natural products 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 239000002253 acid Substances 0.000 description 11
- 239000000306 component Substances 0.000 description 11
- 239000003925 fat Substances 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 229940088594 vitamin Drugs 0.000 description 10
- 229930003231 vitamin Natural products 0.000 description 10
- 235000013343 vitamin Nutrition 0.000 description 10
- 239000011782 vitamin Substances 0.000 description 10
- 208000008589 Obesity Diseases 0.000 description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 9
- 235000019197 fats Nutrition 0.000 description 9
- 235000020824 obesity Nutrition 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 229920001296 polysiloxane Polymers 0.000 description 7
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 241001474374 Blennius Species 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 235000015197 apple juice Nutrition 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- ACXGEQOZKSSXKV-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O.CCCCCCCC(O)=O ACXGEQOZKSSXKV-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 239000001023 inorganic pigment Substances 0.000 description 5
- XDOFQFKRPWOURC-UHFFFAOYSA-N iso-octadecanoic acid Natural products CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 5
- 229960004063 propylene glycol Drugs 0.000 description 5
- 235000013772 propylene glycol Nutrition 0.000 description 5
- 229960000984 tocofersolan Drugs 0.000 description 5
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 4
- ZCTQGTTXIYCGGC-UHFFFAOYSA-N Benzyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 ZCTQGTTXIYCGGC-UHFFFAOYSA-N 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 231100000021 irritant Toxicity 0.000 description 4
- 239000002085 irritant Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 230000037384 skin absorption Effects 0.000 description 4
- 231100000274 skin absorption Toxicity 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- 241000589220 Acetobacter Species 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 235000019482 Palm oil Nutrition 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000002280 amphoteric surfactant Substances 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- MVLVMROFTAUDAG-UHFFFAOYSA-N ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC MVLVMROFTAUDAG-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 229940089456 isopropyl stearate Drugs 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 208000006132 lipodystrophy Diseases 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000012860 organic pigment Substances 0.000 description 3
- 239000002540 palm oil Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000002076 α-tocopherol Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 2
- PYJQLUORHGLSGS-UHFFFAOYSA-N 16-methylheptadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC(C)C PYJQLUORHGLSGS-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- YRXGUZPUZBCGST-UHFFFAOYSA-N [2-(hydroxymethoxy)phenyl]-phenylmethanone Chemical compound OCOC1=CC=CC=C1C(=O)C1=CC=CC=C1 YRXGUZPUZBCGST-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 229910000423 chromium oxide Inorganic materials 0.000 description 2
- 235000019987 cider Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- RAPXDXJBAYUBHI-UHFFFAOYSA-N decyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCCCCCC RAPXDXJBAYUBHI-UHFFFAOYSA-N 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000010445 mica Substances 0.000 description 2
- 229910052618 mica group Inorganic materials 0.000 description 2
- 229940105132 myristate Drugs 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 235000019488 nut oil Nutrition 0.000 description 2
- 239000010466 nut oil Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- PIUVNPNBPWVVKZ-UHFFFAOYSA-N octadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC PIUVNPNBPWVVKZ-UHFFFAOYSA-N 0.000 description 2
- 229960001679 octinoxate Drugs 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- RLUCXJBHKHIDSP-UHFFFAOYSA-N propane-1,2-diol;propanoic acid Chemical compound CCC(O)=O.CC(O)CO RLUCXJBHKHIDSP-UHFFFAOYSA-N 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- DEQUKPCANKRTPZ-UHFFFAOYSA-N (2,3-dihydroxyphenyl)-phenylmethanone Chemical compound OC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1O DEQUKPCANKRTPZ-UHFFFAOYSA-N 0.000 description 1
- BOCBOJPUWMTAJB-UHFFFAOYSA-N (2-butylphenyl) 2-hydroxybenzoate Chemical compound CCCCC1=CC=CC=C1OC(=O)C1=CC=CC=C1O BOCBOJPUWMTAJB-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 description 1
- FIDRAVVQGKNYQK-UHFFFAOYSA-N 1,2,3,4-tetrahydrotriazine Chemical compound C1NNNC=C1 FIDRAVVQGKNYQK-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- SAMYFBLRCRWESN-UHFFFAOYSA-N 16-methylheptadecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC(C)C SAMYFBLRCRWESN-UHFFFAOYSA-N 0.000 description 1
- ZMXUPLNMYABPEB-UHFFFAOYSA-N 2-[[2-(dodecanoylamino)acetyl]amino]acetic acid Chemical compound CCCCCCCCCCCC(=O)NCC(=O)NCC(O)=O ZMXUPLNMYABPEB-UHFFFAOYSA-N 0.000 description 1
- AKVBCGQVQXPRLD-UHFFFAOYSA-N 2-aminooctanoic acid Chemical compound CCCCCCC(N)C(O)=O AKVBCGQVQXPRLD-UHFFFAOYSA-N 0.000 description 1
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 description 1
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 1
- GLCFQKXOQDQJFZ-UHFFFAOYSA-N 2-ethylhexyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(CC)CCCC GLCFQKXOQDQJFZ-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 1
- HTNFLUQQANUSLR-UHFFFAOYSA-N 2-octanoyloxyethyl octanoate Chemical compound CCCCCCCC(=O)OCCOC(=O)CCCCCCC HTNFLUQQANUSLR-UHFFFAOYSA-N 0.000 description 1
- GECRRQVLQHRVNH-MRCUWXFGSA-N 2-octyldodecyl (z)-octadec-9-enoate Chemical compound CCCCCCCCCCC(CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC GECRRQVLQHRVNH-MRCUWXFGSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- SDZHIRPZKXFSBX-UHFFFAOYSA-N 3-(dodecanoylamino)propanoic acid;zinc Chemical compound [Zn].CCCCCCCCCCCC(=O)NCCC(O)=O SDZHIRPZKXFSBX-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- BCNMHJYHRSTPJY-UHFFFAOYSA-N 8-methylnonyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCC(C)C BCNMHJYHRSTPJY-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
- 208000011582 Abnormality of the lymphatic system Diseases 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical compound NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- QVNCZVPOUKXBBQ-UHFFFAOYSA-N C(CCCCCCCCCCC)(=O)OCCCCCCCCCCCC.[Ca] Chemical compound C(CCCCCCCCCCC)(=O)OCCCCCCCCCCCC.[Ca] QVNCZVPOUKXBBQ-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 244000260524 Chrysanthemum balsamita Species 0.000 description 1
- 235000005633 Chrysanthemum balsamita Nutrition 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 1
- RDOFJDLLWVCMRU-UHFFFAOYSA-N Diisobutyl adipate Chemical compound CC(C)COC(=O)CCCCC(=O)OCC(C)C RDOFJDLLWVCMRU-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- PYVHTIWHNXTVPF-UHFFFAOYSA-N F.F.F.F.C=C Chemical compound F.F.F.F.C=C PYVHTIWHNXTVPF-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004640 Melamine resin Substances 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- NKSOSPOXQKNIKJ-CLFAGFIQSA-N Polyoxyethylene dioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOC(=O)CCCCCCC\C=C/CCCCCCCC NKSOSPOXQKNIKJ-CLFAGFIQSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 239000001744 Sodium fumarate Substances 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 240000000377 Tussilago farfara Species 0.000 description 1
- 235000004869 Tussilago farfara Nutrition 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- WUBKCBOQNXUQDU-UHFFFAOYSA-N [2-(dihydroxymethoxy)phenyl]-phenylmethanone Chemical compound OC(O)OC1=CC=CC=C1C(=O)C1=CC=CC=C1 WUBKCBOQNXUQDU-UHFFFAOYSA-N 0.000 description 1
- SVRHJWALMLOXMI-UHFFFAOYSA-N [2-(dihydroxymethoxy)phenyl]-phenylmethanone;sodium Chemical compound [Na].OC(O)OC1=CC=CC=C1C(=O)C1=CC=CC=C1 SVRHJWALMLOXMI-UHFFFAOYSA-N 0.000 description 1
- KSHPUQQHKKJVIO-UHFFFAOYSA-N [Na].[Zn] Chemical compound [Na].[Zn] KSHPUQQHKKJVIO-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- HZSIFDFXFAXICF-UHFFFAOYSA-N acetolactone Chemical compound O=C1CO1 HZSIFDFXFAXICF-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N anhydrous gallic acid Natural products OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- YSJGOMATDFSEED-UHFFFAOYSA-M behentrimonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)C YSJGOMATDFSEED-UHFFFAOYSA-M 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 239000001518 benzyl (E)-3-phenylprop-2-enoate Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- NGHOLYJTSCBCGC-QXMHVHEDSA-N benzyl cinnamate Chemical compound C=1C=CC=CC=1\C=C/C(=O)OCC1=CC=CC=C1 NGHOLYJTSCBCGC-QXMHVHEDSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- HGKOWIQVWAQWDS-UHFFFAOYSA-N bis(16-methylheptadecyl) 2-hydroxybutanedioate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CC(O)C(=O)OCCCCCCCCCCCCCCCC(C)C HGKOWIQVWAQWDS-UHFFFAOYSA-N 0.000 description 1
- WMNULTDOANGXRT-UHFFFAOYSA-N bis(2-ethylhexyl) butanedioate Chemical compound CCCCC(CC)COC(=O)CCC(=O)OCC(CC)CCCC WMNULTDOANGXRT-UHFFFAOYSA-N 0.000 description 1
- JHXKRIRFYBPWGE-UHFFFAOYSA-K bismuth chloride Chemical compound Cl[Bi](Cl)Cl JHXKRIRFYBPWGE-UHFFFAOYSA-K 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DHAZIUXMHRHVMP-UHFFFAOYSA-N butyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCC DHAZIUXMHRHVMP-UHFFFAOYSA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- AGNCRIYGRWNVIF-UHFFFAOYSA-N calcium;2-(dodecanoylamino)acetic acid Chemical compound [Ca].CCCCCCCCCCCC(=O)NCC(O)=O AGNCRIYGRWNVIF-UHFFFAOYSA-N 0.000 description 1
- CEGYXKLZALIAEI-UHFFFAOYSA-N calcium;2-(dodecanoylamino)ethanesulfonic acid Chemical compound [Ca].CCCCCCCCCCCC(=O)NCCS(O)(=O)=O CEGYXKLZALIAEI-UHFFFAOYSA-N 0.000 description 1
- YEFORLIOCBRMFS-UHFFFAOYSA-N calcium;2-(hexadecanoylamino)ethanesulfonic acid Chemical compound [Ca].CCCCCCCCCCCCCCCC(=O)NCCS(O)(=O)=O YEFORLIOCBRMFS-UHFFFAOYSA-N 0.000 description 1
- HOQGRRFKKLWWOO-UHFFFAOYSA-N calcium;3-(dodecanoylamino)propanoic acid Chemical compound [Ca].CCCCCCCCCCCC(=O)NCCC(O)=O HOQGRRFKKLWWOO-UHFFFAOYSA-N 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- VQWFNAGFNGABOH-UHFFFAOYSA-K chromium(iii) hydroxide Chemical compound [OH-].[OH-].[OH-].[Cr+3] VQWFNAGFNGABOH-UHFFFAOYSA-K 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- NGHOLYJTSCBCGC-UHFFFAOYSA-N cis-cinnamic acid benzyl ester Natural products C=1C=CC=CC=1C=CC(=O)OCC1=CC=CC=C1 NGHOLYJTSCBCGC-UHFFFAOYSA-N 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- WVWRBUIUZMBLNI-UHFFFAOYSA-N decyl octanoate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC WVWRBUIUZMBLNI-UHFFFAOYSA-N 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 229940031769 diisobutyl adipate Drugs 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- MIMDHDXOBDPUQW-UHFFFAOYSA-N dioctyl decanedioate Chemical compound CCCCCCCCOC(=O)CCCCCCCCC(=O)OCCCCCCCC MIMDHDXOBDPUQW-UHFFFAOYSA-N 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000004664 distearyldimethylammonium chloride (DHTDMAC) Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
- 229940031016 ethyl linoleate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940093476 ethylene glycol Drugs 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- FPMPNVIMFPEKRN-UHFFFAOYSA-N hexyl 16-methylheptadecanoate Chemical compound CCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C FPMPNVIMFPEKRN-UHFFFAOYSA-N 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 229960004881 homosalate Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940093629 isopropyl isostearate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 229940060384 isostearyl isostearate Drugs 0.000 description 1
- 229940113915 isostearyl palmitate Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000019988 mead Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- LAQFLZHBVPULPL-UHFFFAOYSA-N methyl(phenyl)silicon Chemical compound C[Si]C1=CC=CC=C1 LAQFLZHBVPULPL-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- NNSWOABHNWRKDR-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine;octadecanoic acid Chemical compound CCN(CC)CCN.CCCCCCCCCCCCCCCCCC(O)=O NNSWOABHNWRKDR-UHFFFAOYSA-N 0.000 description 1
- RVRFYZGKUZFYAH-UHFFFAOYSA-N n',n'-dimethylpropane-1,3-diamine;octadecanoic acid Chemical compound CN(C)CCCN.CCCCCCCCCCCCCCCCCC(O)=O RVRFYZGKUZFYAH-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- VAMFXQBUQXONLZ-UHFFFAOYSA-N n-alpha-eicosene Natural products CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 1
- GQEZCXVZFLOKMC-UHFFFAOYSA-N n-alpha-hexadecene Natural products CCCCCCCCCCCCCCC=C GQEZCXVZFLOKMC-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000010702 perfluoropolyether Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- LYKRPDCJKSXAHS-UHFFFAOYSA-N phenyl-(2,3,4,5-tetrahydroxyphenyl)methanone Chemical compound OC1=C(O)C(O)=CC(C(=O)C=2C=CC=CC=2)=C1O LYKRPDCJKSXAHS-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
- 229940033329 phytosphingosine Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920005668 polycarbonate resin Polymers 0.000 description 1
- 239000004431 polycarbonate resin Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- XEIOPEQGDSYOIH-MURFETPASA-N propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(C)C XEIOPEQGDSYOIH-MURFETPASA-N 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229940116422 propylene glycol dicaprate Drugs 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000010499 rapseed oil Substances 0.000 description 1
- 229940077082 red pepper extract Drugs 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940005573 sodium fumarate Drugs 0.000 description 1
- 235000019294 sodium fumarate Nutrition 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 150000003410 sphingosines Chemical class 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 229940117986 sulfobetaine Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- SZEMGTQCPRNXEG-UHFFFAOYSA-M trimethyl(octadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C SZEMGTQCPRNXEG-UHFFFAOYSA-M 0.000 description 1
- 229940113165 trimethylolpropane Drugs 0.000 description 1
- APVVRLGIFCYZHJ-UHFFFAOYSA-N trioctyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CCCCCCCCOC(=O)CC(O)(C(=O)OCCCCCCCC)CC(=O)OCCCCCCCC APVVRLGIFCYZHJ-UHFFFAOYSA-N 0.000 description 1
- COXJMKGEQAWXNP-UHFFFAOYSA-N tris(14-methylpentadecyl) 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CC(C)CCCCCCCCCCCCCOC(=O)CC(O)(C(=O)OCCCCCCCCCCCCCC(C)C)CC(=O)OCCCCCCCCCCCCCC(C)C COXJMKGEQAWXNP-UHFFFAOYSA-N 0.000 description 1
- AGBVGLJAIGBYAD-UHFFFAOYSA-N tris(2-methylpropyl) 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CC(C)COC(=O)CC(O)(C(=O)OCC(C)C)CC(=O)OCC(C)C AGBVGLJAIGBYAD-UHFFFAOYSA-N 0.000 description 1
- RHNXTZDKMRCKKT-UHFFFAOYSA-N tris(6-methylheptyl) 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CC(C)CCCCCOC(=O)CC(O)(C(=O)OCCCCCC(C)C)CC(=O)OCCCCCC(C)C RHNXTZDKMRCKKT-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 바이오셀룰로오스 분말을 유효성분으로 함유하는 조성물에 관한 것으로, 구체적으로 본 발명의 바이오 셀룰로오스를 사용한 모든 피험자를 대상으로 한 안티셀룰라이트 효과실험을 통하여 진피와 피하지방 경계면 두께를 유의하게 감소시키고 제품 사용 전과 비교시 제품 사용 후 대퇴부의 탄력성이 유의하게 개선되었으며(실험예 1); 피험자에 의한 유효성 설문조사(Global Assessment of Efficacy by Patient)에서 시험제품 사용 후 피험자가 느끼는 셀룰라이트 감소 정도 실험에서도 유의적인 셀룰라이트 제거 및 피부 탄력성개선 효과를 나타내므로(실험예 2), 피부결을 매끄럽게 가꾸고 처짐을 방지하기 위한 미용 용도로서도 사용가능함을 확인하여 셀룰라이트 감소 및 예방용 피부외용 약학조성물 및 화장료 조성물로 유용하게 이용될 수 있다.The present invention relates to a composition containing a bio-cellulose powder as an active ingredient, and more specifically, to an anti-cellulite effect test on all subjects using the bio-cellulose of the present invention, the dermal and subcutaneous fat interface thicknesses are significantly reduced The elasticity of the femur after use of the product was significantly improved (Experimental Example 1) compared with before use of the product; In the Global Assessment of Efficacy by Patient, the subject's cellulite reduction test after the use of the test product showed significant cellulite removal and skin elasticity improvement (Experimental Example 2) It can be used as a cosmetic application for preventing smoothing and sagging. Therefore, it can be usefully used as an external dermatological pharmaceutical composition and a cosmetic composition for reducing and preventing cellulite.
Description
본 발명은 바이오셀룰로오스의 분말을 유효성분으로 함유하는 셀룰라이트 감소 및 예방용 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for reducing and preventing cellulite containing a powder of bio-cellulose as an active ingredient.
[문헌 1] 한국특허 공개 제10-2012-0090137호[Patent Document 1] Korean Patent Publication No. 10-2012-0090137
[문헌 2] 한국공개특허 제2015-0072797호[Patent Document 2] Korean Published Patent Application No. 2015-0072797
[문헌 3] Method of testing primary irritant substances 38(187): pp 1500-1541[Literature 3] Method of testing primary irritant substances 38 (187): pp 1500-1541
최근 들어 생활수준의 향상으로 피부 미용에 대한 관심과 기대가 증가하면서, 여성들의 화장품 특히 기능성 미용제품에 대한 관심이 날로 고조되고 특수한 기능을 부여하는 슬리밍 제품에 대한 관심도 계속 증가되고 있다.In recent years, interest in and expectation of skin beauty has increased with the improvement of living standards, and there is a growing interest in slimming products in which the interest of women in cosmetics, especially functional beauty products,
국소 비만은 복부, 둔대퇴부 등의 특정 부위에 과도하게 지방이 침착된 것으로, 내분비적, 해부학적 요인에 의해 여성에게 더욱 흔하게 나타난다. 국소 비만은 건강과 삶의 질에 직접적인 영향을 주고, 미용 성형적 측면에서도 개인의 심리적 위축과 사회적 부적응을 초래한다는 점에서 그 의미가 특별하다.Local obesity is an excess fat deposition in certain areas such as the abdomen and stomach, and is more common in women due to endocrine and anatomical factors. Local obesity has a direct effect on health and quality of life, and it is especially meaningful in that it causes psychological atrophy and social maladjustment in the aspect of cosmetic molding.
지방이영양증(lipodystrophy)은 피하 결합조직의 일정한 부위에 국한한 지방질의 과잉에 기인한 것으로, 100㎛ 이상의 구상 지방세포로 이루어진 과형성된 지방소엽이 나타난다. 진피내 신진대사 기능의 결함으로 섬유아세포가 증식하고 국소적 정맥-림프 체계가 정체되면서 시작되며, 이에 따른 콜라겐의 생성, 섬유 증식 강화, 오렌지 피부 및 부종을 동반한다. 이러한 증상들이 더욱 진행되면 섬유화 및 경피화된 막질융기질환이 나타나며, 이는 비만증과 달리 식이 조절이나 운동으로도 개선시키기 어렵다.Lipodystrophy is caused by an excess of lipid localized in a certain region of subcutaneous connective tissue, and hyperplastic fat lobules composed of globular fat cells of 100 μm or more appear. Defects in the metabolism of the dermis begin with fibroblast proliferation and local stenosis of the venous-lymph system, resulting in collagen production, fiber proliferation enhancement, orange skin and edema. As these symptoms progress further, fibrosis and transdermal membranous bulbous diseases appear, unlike obesity, it is difficult to control diet or exercise.
셀룰라이트(cellulite)는 지방이영양증과 같은 병리에 의해 발생하지만 지방이영양증보다는 협소한 의미라고 할 수 있다. 셀룰라이트는 과도한 지방과 노폐물의 축적에 의한 순환장애로 피부가 거친 오렌지 껍질 같이 울퉁불퉁하게 되는 현상으로, 콜라겐과 엘라스틴이 존재하는 피부의 진피층 내에서 생성되며 여성에서 특히 빈번하게 발생한다. 셀룰라이트 비만은 피하 지방조직의 이상 누적 외에도 임파체계의 이상으로 임파액이 인체 조직 간극에 정체됨으로써 그 부위에 일종의 부종현상이 나타나 마치 살이 찐 것처럼 보이는 것으로, 체형 변화의 큰 요인이 된다. 조직 간극에 임파액이 정체되면 비만증과 같은 미용상의 문제뿐만 아니라 체내에 독성물질이 누적되어 피부세포에 악영향을 끼치고 세포의 영양섭취를 위한 이온화 활동을 저해하여 피부의 노화는 물론 세포의 괴사현상까지 유발하게 된다.Cellulite is caused by pathologies like lipodystrophy, but it is narrower than fat lipodystrophy. Cellulite is a circulatory disorder caused by the accumulation of excessive fats and waste, which causes the skin to become rugged like a rough orange skin. It is produced in the dermal layer of the skin where collagen and elastin are present, and occurs particularly frequently in women. Cellulite obesity is not only abnormal accumulation of subcutaneous adipose tissue but also lymphatic system is stagnated in the interstitial space of the human body due to abnormality of the lymphatic system, and a kind of swelling phenomenon appears at that site, and it looks like it is steamed. If the lymphatic fluid stagnates in the interstitial space, not only the cosmetic problems such as obesity but also accumulation of toxic substances in the body adversely affect the skin cells and inhibit the ionization activity for the nutrition of the cells, thereby causing not only skin aging but also cell necrosis .
이와 같이, 지방이영양증 및 셀룰라이트의 발생 원인은 단순한 비만과는 차이가 있는 것으로 알려져 있다(한국특허 공개 제10-2012-0090137호). As described above, it is known that the cause of fat dystrophy and cellulite is different from mere obesity (Korean Patent Laid-Open Publication No. 10-2012-0090137).
이와 같이, 건강의 측면에서뿐만 아니라 여성의 사회적 지위 향상과 경제적 독립 등의 사회적인 환경 변화에 의해 삶의 질을 높이고자 하는 욕구가 증가하게 됨으로써 미의 관점에서 아름다운 몸매에 대한 관심도 또한 급격히 증가하고 있는 추세이다. 현재 많은 여성들이 성형수술에 대한 심리적 부담감, 비용, 부작용 등으로 인해 상대적으로 안전하고 저렴한 제품인 슬리밍(slimming) 및 안티 셀룰라이트(anti-celullite) 화장품에 대한 요구가 꾸준히 높아지고 있다.In this way, not only in terms of health, but also in the desire to improve the quality of life by social changes such as the improvement of women's social status and economic independence, interest in beautiful body is also increasing rapidly to be. Currently, many women are increasingly demanding relatively safe and cheap products such as slimming and anti-celullite cosmetics due to the psychological burden of cosmetic surgery, cost, and side effects.
한편, 기존의 슬리밍 바디 케어 제품들은 식욕억제 약물 또는 이뇨제에 의한 일시적인 효과를 이용한 것에 불과하였고 어지러움, 구토, 불면증, 환각 증세 등의 부작용이 있었다. 지방은 식이요법 또는 운동을 통해 쉽게 제거되지만, 셀룰라이트는 그 제거가 쉽지 않은 문제점이 있기 때문에 셀룰라이트 제거 전용 슬리밍 제품들에 대한 수요가 증가하고 있다. On the other hand, conventional slimming body care products are merely a temporary effect of an appetite suppressant drug or diuretic, and have side effects such as dizziness, vomiting, insomnia and hallucination. Fat is easily removed by diet or exercise, but there is an increasing demand for cellulite removal slimming products because cellulite is not easy to remove.
종래 기술은, 한국공개특허 제2015-0072797호처럼 지방분해 또는 셀룰라이트 감소 물질로 카페인을 포함하는데, 카페인은 중독성 물질이라는 인식과 기관지 확장, 월경 전 증후군 현상의 악화 같은 부작용이 보고되어 있다. The prior art discloses caffeine as a lipid degradation or cellulite reducing substance as disclosed in Korean Laid-Open Patent Application No. 2015-0072797, and caffeine is known to be a toxic substance, and side effects such as bronchodilation and deterioration of the premenstrual syndrome phenomenon have been reported.
따라서, 셀룰라이트 감소 효과를 가지면서 부작용이 없는 천연물 소재, 또는 강력한 셀룰라이트 감소 효과를 보이는 천연물 소재를 개발요구가 지속되어 왔다Accordingly, there has been a demand for development of a natural material having a cellulite reducing effect and no side effects, or a natural material having a strong cellulite reducing effect
그러나, 상기 문헌의 어디에도 바이오셀룰로오스의 분말을 유효성분으로 함유하는 셀룰라이트 감소 및 예방효과에 대하여 언급되거나 개시된 바는 없다However, none of the above documents mention or disclose the cellulite reducing and preventing effect of containing a powder of bio-cellulose as an active ingredient
본원 발명자들은 본 발명의 바이오 셀룰로오스 분말을 사용한 모든 피험자를 대상으로 한 안티셀룰라이트 효과실험을 통하여 진피와 피하지방 경계면 두께를 유의하게 감소시키고 제품 사용 전과 비교시 제품 사용 후 대퇴부의 탄력성이 유의하게 개선되었으며(실험예 1); 피험자에 의한 유효성 설문조사(Global Assessment of Efficacy by Patient)에서 시험제품 사용 후 피험자가 느끼는 셀룰라이트 감소 정도 실험에서도 유의적인 셀룰라이트 제거 및 피부 탄력성개선 효과를 나타내므로(실험예 2), 피부결을 매끄럽게 가꾸고 처짐을 방지하기 위한 미용 용도로서도 사용가능함을 확인하여 본 발명을 완성하였다.The inventors of the present invention found that the anti-cellulite effect test for all subjects using the bio-cellulose powder of the present invention significantly reduced the dermal and subcutaneous fat interface thicknesses and significantly improved the elasticity of the thigh after use of the product (Experimental Example 1); In the Global Assessment of Efficacy by Patient, the subject's cellulite reduction test after the use of the test product showed significant cellulite removal and skin elasticity improvement (Experimental Example 2) It can be used as a cosmetic application for preventing smoothing and sagging, thus completing the present invention.
상기 목적을 달성하기 위하여, 본 발명은 바이오셀룰로오스의 분말을 유효성분으로 함유하는 셀룰라이트 감소 및 예방용 피부외용 약학조성물을 제공한다.In order to achieve the above object, the present invention provides a dermatological pharmaceutical composition for reducing and preventing cellulite containing a powder of bio-cellulose as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 바이오셀룰로오스의 분말을 유효성분으로 함유하는 셀룰라이트 감소 및 개선용 화장료 조성물을 제공한다.In order to achieve the above object, the present invention provides a cosmetic composition for reducing and improving cellulite containing a powder of bio-cellulose as an active ingredient.
본원에서 정의되는 “상기 바이오셀룰로오스는 미생물 셀룰로오스, 과당(Fructose) 및 수분으로 구성됨을 특징으로 하며,The term " bio-cellulose " as defined herein is characterized in that it is composed of microbial cellulose, fructose and water,
보다 구체적으로, 상기 바이오셀룰로오스는 미생물 셀룰로오스 45 - 60 중량 %, 과당(Fructose) 40 - 55 중량 % 및 수분 3 - 6 중량 %, 바람직하게는 미생물 셀룰로오스 50 중량 %, 과당 45 중량 % 및 수분 5 중량 %로 구성되는 것이다.More specifically, the bio-cellulose comprises 45-60% by weight of microbial cellulose, 40-55% by weight of fructose and 3-6% by weight of water, preferably 50% by weight of microbial cellulose, 45% by weight of fructose and 5% %.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 바이오셀룰로오스의 분말은 미생물 셀룰로오스에 과당 및 수분을 첨가하여 하기와 같은 제조공정을 통하여 제조가능한데,The bio-cellulose powder of the present invention can be produced by adding fructose and water to microbial cellulose through the following manufacturing process,
예를 들어, 미생물 셀룰로오스로부터 바이오셀룰로오스를 제조하기 위한 제조공정을 보다 구체적으로 설명하면,For example, a manufacturing process for producing bio-cellulose from microbial cellulose will be described in more detail.
미생물 셀룰로오스는 미생물 셀룰로오스 생산균주, 바람직하게는 아세토박터(Acetobacter)속 균주, 보다 바람직하게는, 아세토박터 자일리윰 (Acetobacter xylinum), 아세토박터 아세티 (Acetobacter aceti), 아세토박터 리퀘파시엔스 (Acetobacter liquefaciens), 아세토박터 파스퉤리아누스 (Acetobacter pasteurianus) 및 아세토박터 한세니이 (Acetobacter hansenii)으로 구성된 군으로부터 선택된 1개 이상의 균주를 미생물 셀룰로오스 생산배지, 바람직하게는 초산과 설탕이 함유된 과일쥬스에 접종하고 진탕 또는 에어 리프트(air lift)형 발효조에서 배양시켜 입자(particle) 또는 침전물(pellet) 모양의 미생물 셀룰로오스가 분산된 형태로 생산 되도록 한 후, 전기 배양액 자체를 초모로 사용하여, 본 배양을 미생물 셀룰로오스 생산배지에 접종하고 정치배양한 다음, 반투명한 겔 상태의 미생물 셀룰로오스를 제조할 수 있다.Microbial cellulose is a microbial cellulose production strain, Preferably a strain belonging to the genus Acetobacter, more preferably a strain selected from the group consisting of Acetobacter xylinum, Acetobacter aceti, Acetobacter liquefaciens, One or more strains selected from the group consisting of Acetobacter pasteurianus and Acetobacter hansenii are inoculated into microbial cellulose production medium, preferably fruit juice containing acetic acid and sugar, and shaken or air- The microorganism cellulosic material is cultured in a fermenter such that particles or pellets of the microorganism cellulosic material are dispersed and then the microorganism cellulosic production medium is cultured Next, a semi-transparent gel-state microbial cellulose can be produced.
또한, 상기와 같은 과정으로 제조된 반투명한 겔 상태의 미생물 셀룰로오스는 그 내부에 배지 성분 및 균체를 함유하고 있으므로, 물에 침지 및 세정하고 가열하여, 불순물이 제거된 겔 상의 미생물 셀룰로오스를 제조 가능하다. In addition, since the translucent gel-state microbial cellulose prepared by the above process contains the medium components and the microbial cells therein, it is possible to produce microbial cellulose gel in which the impurities are removed by immersion in water, washing and heating .
이러한 겔 상의 미생물 셀룰로오스는 스폰지 또는 여과포를 이용하여 공압 또는 유압 압착기에서 압착하여 약 0.4 - 0.8mm 정도의 웨트 시이트(wet sheet)로 제조 될 수 있으며, 상기 제조된 웨트 시이트는 건조 시킨 후 분쇄가 용이 하도록 하기 위하여, 3 - 10% 과당 또는 설탕 용액 또는 부형제에 침지하여 미생물 셀룰로오스 웨트 시이트가 과당 또는 설탕 용액 또는 부형제를 흡수하도록 하여 웨트 시이트 두께가 2 - 4mm로 복원되도록 하고, 복원된 미생물 셀룰로오스 웨트 시이트를 공압 또는 유압 압착기로 재차 압착하여 두께 약 0.4 - 0.8mm인 바이오셀룰로오스 웨트 시이트가 제조 될수 있다.The gel-like microbial cellulose can be produced by wet-sheet of about 0.4 - 0.8 mm by pressing in a pneumatic or hydraulic press using a sponge or a filter cloth, and the wet sheet is dried and then easily pulverized , So that the microcellular cellulose wet sheet absorbs the fructose or sugar solution or the excipient so as to restore the wet sheet thickness to 2-4 mm, and the restored microbial cellulose wet sheet Is compressed again with a pneumatic or hydraulic press to obtain a bio-cellulose wet sheet having a thickness of about 0.4 to 0.8 mm.
또한, 상기 바이오셀룰로오스 웨트 시이트를 건조실에서 열풍 또는 동결 건조시킨 후, 건조된 시이트를 건식 분쇄기로 분쇄하여 30 - 50 메시(mesh) 체에 통과 시켜 본 발명의 바이오셀룰로오스 분말을 수득할 수 있다.In addition, after the bio-cellulose wet sheet is dried in hot air or freeze-dried in a drying chamber, the dried sheet is pulverized with a dry pulverizer and passed through a 30-50 mesh sieve to obtain the bio-cellulose powder of the present invention.
상기 바이오셀룰로오스 분말은 (a) 미생물 셀룰로오스 생산균주를 pH 2 내지 5로 적정한 미생물 셀룰로오스 생산배지에 접종하는 제 1단계; 상기 미생물 셀룰로오스 생산배지를 10 내지 50℃ 온도에서 50 내지 500rpm 조건하에서 6시간 내지 71시간 동안 진탕 또는 에어 리프트(air lift)형 발효조에서 배양시켜 입자(particle) 또는 침전물(pellet)모양의 미생물 셀룰로오스가 분산된 형태로 생산된 배양액을 제조하는 제 2단계; 상기 2단계의 배양액 자체를 초모로 사용하여, 본 배양을 pH 2 내지 5로 적정한 미생물 셀룰로오스 생산배지에 1 내지 20%(v/v)의 양으로 접종하고 12시간 내지 24일 동안 정치배양하여 반투명한 겔 상태의 미생물 셀룰로오스를 수득하는 제 3단계; 상기 3단계에서 제조한 1 내지 12mm의 내부에 배지 성분 및 균체를 함유한 반투명 겔 상의 미생물 셀룰로오스를 물에 6시간 내지 4일간 침지하고 물로 1 내지 5회 세정하고 60 내지 140℃에서 10분 내지 120시간 가열하여 불순물을 제거하는 제 4단계; 상기 4단계에서 얻은 불순물이 제거된 겔 상의 미생물 셀룰로오스를 압착기에서 스폰지를 이용하여 두께 0.2 내지 1.2mm 정도로 압착하여 수분 함량 75 - 99%의 미생물 셀룰로오스 웨트 시이트(wet sheet)를 제조하는 제 5단계; 상기 제 5단계에서 수득한 웨트 시이트를 과당용액에 30 내지 240분간 침지시키는 제 6단계; 제 6단계의 침지 후, 침지된 미생물 셀룰로오스를 과당액을 재 흡수하여 두께 1 내지 6mm로 복원시키는 제 7단계; 제 7단계의 복원된 미생물 셀룰로오스를 압착기로 재차 압착하여 두께 0.1 내지 1.4mm의 바이오셀룰로오스 웨트 시이트를 제조하는 제 8단계; 제 8단계에서 제조된 바이오셀룰로오스 웨트 시이트를 30 내지 100 ℃의 건조실에서 6 시간 내지 36 시간 동안 건조시키는 제 9단계; 제 9단계의 건조된 시이트를 건식 분쇄기로 분쇄하여 10 내지 80 메시(mesh) 체에 통과시키는 제 10단계 공정으로 제조됨을 특징으로 한다.The bio-cellulose powder comprises: (a) a step of inoculating a microorganism-cellulose-producing strain with a pH of 2 to 5 into a microorganism-cellulose producing medium; The microbial cellulose production medium is cultured in a shaking or air lift type fermentation tank at a temperature of 10 to 50 DEG C under a condition of 50 to 500 rpm for 6 to 71 hours to produce microbial cellulose in the form of a particle or a pellet A second step of producing a culture solution produced in a dispersed form; The culture of step 2 itself is used as a hair transplantation, and the present culture is inoculated in an amount of 1 to 20% (v / v) in a microorganism cellulose production medium titrated to a pH of 2 to 5 and cultured for 12 to 24 days to give translucent A third step of obtaining a gel-state microbial cellulose; The microbial cellulose in the form of a translucent gel containing the medium components and cells in the 1 to 12 mm prepared in step 3 is immersed in water for 6 to 4 days, washed 1 to 5 times with water and incubated at 60 to 140 캜 for 10 to 120 A fourth step of removing impurities by heating for a time; A fifth step of producing a microbial cellulose wet sheet having a water content of 75 to 99% by pressing the gel-like microbial cellulose obtained in the step 4 in a thickness of about 0.2 to 1.2 mm using a sponge in a press machine; A sixth step of immersing the wet sheet obtained in the fifth step in a fructose solution for 30 to 240 minutes; A seventh step of reabsorbing the microbial cellulose immersed after the immersion in the sixth step to a thickness of 1 to 6 mm; An eighth step of producing a bio-cellulose wet sheet having a thickness of 0.1 to 1.4 mm by re-pressing the restored micro-organism cellulose of the seventh step with a compactor; A ninth step of drying the biocellulose wet sheet prepared in the eighth step in a drying chamber at 30 to 100 DEG C for 6 to 36 hours; The dried sheet of the ninth step is pulverized by a dry mill and passed through a 10 to 80 mesh sieve.
따라서, 본 발명은 (a) 미생물 셀룰로오스 생산균주, 바람직하게는 아세토박터(Acetobacter)속 균주, 보다 바람직하게는, 아세토박터 자일리윰 (Acetobacter xylinum), 아세토박터 아세티 (Acetobacter aceti), 아세토박터 리퀘파시엔스 (Acetobacter liquefaciens), 아세토박터 파스퉤리아누스 (Acetobacter pasteurianus) 및 아세토박터 한세니이 (Acetobacter hansenii)으로 구성된 군으로부터 선택된 1개 이상의 균주를 pH 2 내지 5, 바람직하게는 3 내지 4로 적정한 미생물 셀룰로오스 생산배지, 바람직하게는 초산과 설탕, 약 0.1 내지 3%(v/v)의 초산과 약 1 내지 30%(v/v)의 설탕이 함유된 약 20 내지 55% 코코넛수 또는 사과 쥬스, 보다 바람직하게는 약 30 내지 45% 코코넛수 또는 사과 쥬스에 접종하는 제 1단계; 상기 미생물 셀룰로오스 생산배지를 10 내지 50℃, 바람직하게는, 20 내지 40℃ 온도에서 약 50 내지 500rpm, 바람직하게는 100 내지 200rpm 조건하에서 6시간 내지 71시간, 바람직하게는 1일 내지 3일 동안 진탕 또는 에어 리프트(air lift)형 발효조에서 배양시켜 입자(particle) 또는 침전물(pellet)모양의 미생물 셀룰로오스가 분산된 형태로 생산된 배양액을 제조하는 제 2단계; 상기 2단계의 배양액 자체를 초모로 사용하여, 본 배양을 pH 2 내지 5, 바람직하게는 3 내지 4로 적정한 미생물 셀룰로오스 생산배지, 바람직하게는, 약 0.1 내지 3%(v/v)의 초산 및 약 1 내지 30%(v/v) 설탕, 보다 바람직하게는 약 0.5 내지 2%(v/v)의 초산 및 약 5 내지 20%(v/v)의 설탕이 함유된 코코넛수 또는 사과 쥬스, 보다 바람직하게는 약 30 내지 45% 설탕이 함유된 코코넛수 또는 사과 쥬스 희석액에 1 내지 20%(v/v), 바람직하게는 5 내지 20%(v/v)의 양으로 접종하고 12시간 내지 24일, 바람직하게는 3일 내지 10일 동안 정치배양하여 반투명한 겔 상태의 미생물 셀룰로오스를 수득하는 제 3단계; 상기 3단계에서 제조한 약 1 내지 12mm, 바람직하게는 5 내지 8㎜ 두께의 내부에 배지 성분 및 균체를 함유한 반투명 겔 상의 미생물 셀룰로오스를 물에 약 6시간 내지 4일간, 바람직하게는 1일 내지 2일간 침지하고 물로 1 내지 5회, 바람직하게는, 1 내지 3회 세정하고 60 내지 140℃, 바람직하게는, 80 내지 120℃에서 약 10분 내지 120시간 , 바람직하게는 20 내지 60 분간 가열하여 불순물을 제거하는 제 4단계; 상기 4단계에서 얻은 불순물이 제거된 겔 상의 미생물 셀룰로오스를 압착기에서 스폰지를 이용하여 두께 약 0.2 내지 1.2mm, 바람직하게는, 약 0.4 - 0.8mm 정도로 압착하여 수분 함량 75 - 99%, 바람직하게는 85 - 95%의 미생물 셀룰로오스 웨트 시이트(wet sheet)를 제조하는 제 5단계; 상기 제 5단계에서 수득한 웨트 시이트를 과당용액, 바람직하게는 1% 내지 20%, 보다 바람직하게는 약 3% 내지 10% 과당 용액에 30 내지 240분, 바람직하게는 60 내지 120분간 침지시키는 제 6단계; 제 6단계의 침지 후, 침지된 미생물 셀룰로오스를 과당액을 재 흡수하여 두께 1 내지 6mm, 바람직하게는, 두께 2 내지 4mm로 복원시키는 제 7단계; 제 7단계의 복원된 미생물 셀룰로오스를 압착기로 재차 압착하여 두께 0.1 내지 1.4mm, 바람직하게는, 0.4 내지 0.8mm의 바이오셀룰로오스 웨트 시이트를 제조하는 제 8단계; 제 8단계에서 제조된 바이오셀룰로오스 웨트 시이트를 30 내지 100 ℃, 바람직하게는, 50 내지 80 ℃의 건조실에서 6 시간 내지 36 시간, 바람직하게는, 12 시간 내지 24 시간 동안 건조시키는 제 9단계; 제 9단계의 건조된 시이트를 건식 분쇄기로 분쇄하여 약, 10 내지 80 메시(mesh), 바람직하게는, 30 내지 50 메시(mesh) 체에 통과시키는 제 10단계 공정을 포함하는 본 발명의 바이오셀룰로오스 분말을 제조하는 제조방법을 제공한다.Therefore, the present invention relates to a microbial cellulase producing strain, preferably a strain of the genus Acetobacter, more preferably a microbial cellulase producing strain, such as Acetobacter xylinum, Acetobacter aceti, At least one strain selected from the group consisting of Acetobacter liquefaciens, Acetobacter pasteurianus and Acetobacter hansenii is cultured in a microorganism having a pH of 2 to 5, preferably 3 to 4, Cellulose production medium, preferably about 20 to 55% coconut water or apple juice, containing about 0.1 to 3% (v / v) acetic acid and about 1 to 30% (v / v) More preferably about 30 to 45% coconut water or apple juice; The microbial cellulose production medium is shaken at a temperature of 10 to 50 캜, preferably 20 to 40 캜, for about 6 to 71 hours, preferably 1 to 3 days, at about 50 to 500 rpm, preferably 100 to 200 rpm Or an air lift type fermenter to produce a culture solution in which microbial cellulose in the form of a particle or a pellet is dispersed; The microbial cellulose production medium, preferably about 0.1 to 3% (v / v) of acetic acid and / or acetic acid, which is suitable for microbial cellulose production using pH 2 to 5, preferably 3 to 4, about 1 to 30% (v / v) sugar, more preferably from about 0.5 to 2% (v / v) of acetic acid and from about 5 to 20% (v / v) number of coconut sugar-containing or cider, More preferably in an amount of 1 to 20% (v / v), preferably 5 to 20% (v / v) in a coconut water or apple juice diluted with about 30 to 45% Culturing the mixture for 24 days, preferably 3 days to 10 days, to obtain a translucent gel-state microbial cellulose; The microbial cellulose in a translucent gel containing the medium components and the microorganism within about 1 to 12 mm, preferably 5 to 8 mm in thickness, prepared in the above step 3 is immersed in water for about 6 hours to 4 days, Followed by washing with water for 1 to 5 times, preferably 1 to 3 times, and heating at 60 to 140 占 폚, preferably at 80 to 120 占 폚 for about 10 minutes to 120 hours, preferably 20 to 60 minutes A fourth step of removing impurities; The gel-like microorganism cellulose obtained in the step 4 is compressed in a compression machine using a sponge to a thickness of about 0.2 to 1.2 mm, preferably about 0.4 to 0.8 mm to obtain a water content of 75 to 99%, preferably 85 - a fifth step of producing a 95% microbial cellulose wet sheet; A wetting agent obtained by immersing the wet sheet obtained in the fifth step in a fructose solution, preferably 1% to 20%, more preferably about 3% to 10% fructose solution for 30 to 240 minutes, preferably 60 to 120 minutes Step 6; A seventh step of reabsorbing the immersed microbial cellulose after the immersion in the sixth step to restore its thickness to 1 to 6 mm, preferably 2 to 4 mm; An eighth step of producing a bio-cellulose wet sheet having a thickness of 0.1 to 1.4 mm, preferably 0.4 to 0.8 mm by re-pressing the restored micro-organism cellulose of the seventh step with a compactor; A ninth step of drying the biocellulose wet sheet produced in the eighth step in a drying room at 30 to 100 DEG C, preferably 50 to 80 DEG C for 6 to 36 hours, preferably 12 to 24 hours; The dried sheet of the ninth step is pulverized by a dry pulverizer and passed through a 10 to 80 mesh, preferably 30 to 50 mesh sieve, to obtain a bio-cellulose of the present invention A method for producing a powder is provided.
본 발명의 상기 제조방법중, 상기 제 6단계 내지 제 8단계는 생략 가능하다 따라서, 본 발명은 (a) 미생물 셀룰로오스 생산균주, 바람직하게는 아세토박터(Acetobacter)속 균주, 보다 바람직하게는, 아세토박터 자일리윰 (Acetobacter xylinum), 아세토박터 아세티 (Acetobacter aceti), 아세토박터 리퀘파시엔스 (Acetobacter liquefaciens), 아세토박터 파스퉤리아누스 (Acetobacter pasteurianus) 및 아세토박터 한세니이 (Acetobacter hansenii)으로 구성된 군으로부터 선택된 1개 이상의 균주를 pH 2 내지 5, 바람직하게는 3 내지 4로 적정한 미생물 셀룰로오스 생산배지, 바람직하게는 초산과 설탕, 약 0.1 내지 3%(v/v)의 초산과 약 1 내지 30%(v/v)의 설탕이 함유된 약 20 내지 55% 코코넛수 또는 사과 쥬스, 보다 바람직하게는 약 30 내지 45% 코코넛수 또는 사과 쥬스에 접종하는 제 1단계; 상기 미생물 셀룰로오스 생산배지를 10 내지 50℃, 바람직하게는, 20 내지 40℃ 온도에서 약 50 내지 500rpm, 바람직하게는 100 내지 200rpm 조건하에서 6시간 내지 71시간, 바람직하게는 1일 내지 3일 동안 진탕 또는 에어 리프트(air lift)형 발효조에서 배양시켜 입자(particle) 또는 침전물(pellet)모양의 미생물 셀룰로오스가 분산된 형태로 생산된 배양액을 제조하는 제 2단계; 상기 2단계의 배양액 자체를 초모로 사용하여, 본 배양을 pH 2 내지 5, 바람직하게는 3 내지 4로 적정한 미생물 셀룰로오스 생산배지, 바람직하게는, 약 0.1 내지 3%(v/v)의 초산 및 약 1 내지 30%(v/v) 설탕, 보다 바람직하게는 약 0.5 내지 2%(v/v)의 초산 및 약 5 내지 20%(v/v)의 설탕이 함유된 코코넛수 또는 사과 쥬스, 보다 바람직하게는 약 30 내지 45% 설탕이 함유된 코코넛수 또는 사과 쥬스 희석액에 1 내지 20%(v/v), 바람직하게는 5 내지 20%(v/v)의 양으로 접종하고 12시간 내지 24일, 바람직하게는 3일 내지 10일 동안 정치배양하여 반투명한 겔 상태의 미생물 셀룰로오스를 수득하는 제 3단계; 상기 3단계에서 제조한 약 1 내지 12mm, 바람직하게는 5 내지 8㎜ 두께의 내부에 배지 성분 및 균체를 함유한 반투명 겔 상의 미생물 셀룰로오스를 물에 약 6시간 내지 4일간, 바람직하게는 1일 내지 2일간 침지하고 물로 1 내지 5회, 바람직하게는, 1 내지 3회 세정하고 60 내지 140℃, 바람직하게는, 80 내지 120℃에서 약 10분 내지 120시간, 바람직하게는 20 내지 60 분간 가열하여 불순물을 제거하는 제 4단계; 상기 4단계에서 얻은 불순물이 제거된 겔 상의 미생물 셀룰로오스를 압착기에서 스폰지를 이용하여 두께 약 0.2 내지 1.2mm, 바람직하게는, 약 0.4 - 0.8mm 정도로 압착하여 수분 함량 75 - 99%, 바람직하게는 85 - 95%의 미생물 셀룰로오스 웨트 시이트(wet sheet)를 제조하는 제 5단계; 상기 제 5단계에서 수득한 웨트 시이트를 30 내지 100 ℃, 바람직하게는, 50 내지 80 ℃의 건조실에서 6 시간 내지 36 시간, 바람직하게는, 12 시간 내지 24 시간 동안 건조시키는 제 6단계; 제 6단계의 건조된 시이트를 건식 분쇄기로 분쇄하여 약, 10 내지 80 메시(mesh), 바람직하게는, 30 내지 50 메시(mesh) 체에 통과시키는 제 7단계 공정을 포함하는 본 발명의 바이오셀룰로오스 분말을 제조하는 제조방법도 제공한다.(A) a microorganism cellulosic producing strain, preferably an Acetobacter strain, more preferably an acetolactone-producing strain, and more preferably, From the group consisting of Acetobacter xylinum, Acetobacter aceti, Acetobacter liquefaciens, Acetobacter pasteurianus and Acetobacter hansenii. One or more selected strains are cultivated in a microbial cellulose production medium suitably pH 2 to 5, preferably 3 to 4, preferably acetic acid and sugar, about 0.1 to 3% (v / v) to about 20 to 55% coconut water or apple juice, more preferably about 30 to 45% coconut water or apple juice, containing sugar, v / v; The microbial cellulose production medium is shaken at a temperature of 10 to 50 캜, preferably 20 to 40 캜, for about 6 to 71 hours, preferably 1 to 3 days, at about 50 to 500 rpm, preferably 100 to 200 rpm Or an air lift type fermenter to produce a culture solution in which microbial cellulose in the form of a particle or a pellet is dispersed; The microbial cellulose production medium, preferably about 0.1 to 3% (v / v) of acetic acid and / or acetic acid, which is suitable for microbial cellulose production using pH 2 to 5, preferably 3 to 4, about 1 to 30% (v / v) sugar, more preferably from about 0.5 to 2% (v / v) of acetic acid and from about 5 to 20% (v / v) number of coconut sugar-containing or cider, More preferably in an amount of 1 to 20% (v / v), preferably 5 to 20% (v / v) in a coconut water or apple juice diluted with about 30 to 45% Culturing the mixture for 24 days, preferably 3 days to 10 days, to obtain a translucent gel-state microbial cellulose; The microbial cellulose in a translucent gel containing the medium components and the microorganism within about 1 to 12 mm, preferably 5 to 8 mm in thickness, prepared in the above step 3 is immersed in water for about 6 hours to 4 days, Followed by washing with water for 1 to 5 times, preferably 1 to 3 times, and heating at 60 to 140 占 폚, preferably at 80 to 120 占 폚 for about 10 minutes to 120 hours, preferably 20 to 60 minutes A fourth step of removing impurities; The gel-like microorganism cellulose obtained in the step 4 is compressed in a compression machine using a sponge to a thickness of about 0.2 to 1.2 mm, preferably about 0.4 to 0.8 mm to obtain a water content of 75 to 99%, preferably 85 - a fifth step of producing a 95% microbial cellulose wet sheet; A sixth step of drying the wet sheet obtained in the fifth step in a drying chamber at 30 to 100 캜, preferably 50 to 80 캜, for 6 to 36 hours, preferably 12 to 24 hours; And a seventh step of pulverizing the dried sheet of the sixth step with a dry pulverizer and passing the pulverized product through a sieve of about 10 to 80 meshes, preferably 30 to 50 meshes, The present invention also provides a manufacturing method for producing a powder.
따라서 본 발명은 상기 제조방법 및 상기 제조방법으로 제조된 바이오셀룰로오스 분말을 유효성분으로 함유하는 셀룰라이트 감소 및 예방용 피부외용 약학조성물 및 화장료 조성물을 제공한다.Accordingly, the present invention provides an external dermatological pharmaceutical composition and a cosmetic composition for reducing or preventing cellulite containing the bio-cellulosic powder prepared by the above-described method and the above-described method as an active ingredient.
상기의 제조공정을 통하여 수득된 바이오셀룰로오스 건조 분말의 5 g 내에는 식이섬유가 약 50.2 % 함유되어 있으며, 또한, 상기 바이오셀룰로오스는 미생물 셀룰로오스, 과당(Fructose) 및 수분으로 구성됨을 특징으로 하며, 보다 구체적으로, 상기 바이오셀룰로오스는 미생물 셀룰로오스 45 - 60 중량 %, 과당(Fructose) 40 - 55 중량 % 및 수분 3 - 6 중량 %, 바람직하게는 미생물 셀룰로오스 50 중량 %, 과당 45 중량 % 및 수분 5 중량 %로 구성되는 것이다.The biocellulose powder contained about 50.2% of dietary fiber within 5 g of the dried cellulose powder obtained through the above-mentioned manufacturing process. The bio-cellulose is characterized by being composed of microbial cellulose, fructose and water, Specifically, the bio-cellulosic is composed of 45-60% by weight of microbial cellulose, 40-55% by weight of fructose and 3-6% by weight of water, preferably 50% by weight of microbial cellulose, 45% by weight of fructose and 5% .
상기 바이오 셀룰로오스의 분말을 유효성분으로 함유하는 피부외용 화장료 조성물은 총 중량에 대하여 0.1 내지 50 중량%으로 포함함을 특징으로 한다.The skin cosmetic composition containing the powder of the bio-cellulose as an active ingredient is characterized by containing 0.1 to 50% by weight based on the total weight of the composition.
본 발명자들은 본 발명의 바이오셀룰로오스의 분말을 사용한 모든 피험자를 대상으로 한 안티셀룰라이트 효과실험을 통하여 진피와 피하지방 경계면 두께를 유의하게 감소시키고 제품 사용 전과 비교시 제품 사용 후 대퇴부의 탄력성이 유의하게 개선되었으며(실험예 1); 피험자에 의한 유효성 설문조사(Global Assessment of Efficacy by Patient)에서 시험제품 사용 후 피험자가 느끼는 셀룰라이트 감소 정도 실험에서도 유의적인 셀룰라이트 제거 및 피부 탄력성개선 효과를 나타내므로(실험예 2), 피부결을 매끄럽게 가꾸고 처짐을 방지하기 위한 미용 용도로서도 사용가능함을 확인하여 셀룰라이트 감소 및 예방용 피부외용 약학조성물 및 화장료 조성물로 사용가능하다. The present inventors have significantly reduced the dermal and subcutaneous fat interface thicknesses through the anti-cellulite effect test on all subjects using the bio-cellulose powder of the present invention, and compared the results before use, the elasticity of the femoral component was significantly (Experimental Example 1); In the Global Assessment of Efficacy by Patient, the subject's cellulite reduction test after the use of the test product showed significant cellulite removal and skin elasticity improvement (Experimental Example 2) It can be used as a cosmetic application for preventing smoothing and sagging. Thus, it can be used as an external dermatological pharmaceutical composition and a cosmetic composition for reducing and preventing cellulite.
따라서, 이하 본 발명의 조성물을 포함하는 화장료 및 의약의 일부 제제예가 제시되나 이에 제한되는 것은 아니다. 본 발명의 기능성 화장료 조성물 또는 약학 조성물은 용액, 현탁액, 에멀젼, 연고, 페이스트, 겔, 크림, 로션, 파우더, 스프레이, 팩, 피부접착용 패치, 드레싱, 함수성 첩부제 또는 비-함수성 첩부제, 계면활성제-함유 클렌징, 오일 등의 형태로, 가능한 가장 우수한 제제를 얻기 위하여 당해 기술분야에 알려진 모든 방식으로 제조될 수 있다.Accordingly, examples of some formulations of cosmetics and medicines containing the composition of the present invention are presented below, but the present invention is not limited thereto. The functional cosmetic composition or pharmaceutical composition of the present invention may be in the form of a solution, suspension, emulsion, ointment, paste, gel, cream, lotion, powder, spray, pack, skin patch, dressing, , Surfactant-containing cleansing, oil, etc., in any manner known in the art to obtain the best possible formulation.
또한, 본 발명의 바이오셀룰로오스의 분말은 독성 및 부작용 등의 문제가 없으며, 피부 첩포 시험에서 무자극 시료임이 입증되었으므로 장기간 사용 시에도 안심하고 사용할 수 있다.In addition, the bio-cellulose powder of the present invention has no problems such as toxicity and side effects, and has proved to be a non-irritant sample in the skin patch test, so that it can be safely used for long-term use.
상기 약학 조성물은 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제, 카타플라스마제 제형, 용액제, 현탁액, 에멀젼, 페이스트, 파우더, 스프레이, 팩, 피부접착용 패치, 드레싱, 함수성 첩부제 또는 비-함수성 첩부제, 계면활성제-함유 클렌징 오일 등의 형태로, 가능한 가장 우수한 제제를 얻기 위하여 당해 기술분야에 알려진 모든 방식으로 제조가능하나 이에 한정되는 것은 아니다. The pharmaceutical composition may be in the form of a cream, gel, patch, spray, ointment, warning agent, lotion, liniment, pasta, cataplasma, solution, May be manufactured in any manner known in the art to obtain the best possible formulation in the form of patches, dressings, hydrodynamic or non-hydrodynamic patches, surfactant-containing cleansing oils, etc., but is not limited thereto .
또한, 상기 화장료 조성물은 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 스프레이, 팩 등과 같은 화장품류 뿐만 아니라, 비누, 클렌징폼, 클렌징 로션, 클렌징 크림, 바디 로션, 바디 크림, 바디 오일, 바디 세정제, 샴푸, 연고, 패취, 화장수, 스킨, 로션, 보디용, 얼굴 마스크 용 등의 팩의 제형을 포함하니, 당해 기술분야에 알려진 모든 방식으로 제조가능하나 이에 한정되는 것은 아니다. The cosmetic composition may be at least one selected from the group consisting of a skin lotion, a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nutrition lotion, a massage cream, a nutrition cream, a moisturizing cream, a hand cream, a foundation, Such as soap, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cream, body oil, body cleanser, shampoo, ointment, patch, lotion, skin, lotion, body, facial mask, etc. Pack, and may be manufactured in any manner known in the art, but is not limited thereto.
또한 본 발명의 피부 외용 제제에는 상기 기재한 성분들 이외에 피부나 점막에 적용되는 화장료나 외용의 의약품ㆍ의약부외품에 배합되는 공지의 각종 성분을 적용량 배합할 수 있다.In addition to the above-described ingredients, the external preparation for skin of the present invention can be blended with various known ingredients to be incorporated in cosmetics applied to skin or mucous membranes, medicines for external use, and quasi-drugs.
본 발명의 조성물은 적용하고자 하는 피부 면적에 따라 적절한 양을 피부에 도포함으로써 적용될 수 있으며, 필요에 따라 하루 1회 내지 수 회 반복하여 사용할 수 있다. 적용하는 양 및 횟수는 개인의 피부 상태, 제형, 투여 대상의 연령, 성별, 체중, 비만 등 증상의 정도, 반응감응성, 적용 기간 등에 따라 필요에 따라 적절히 증감할 수 있다.The composition of the present invention can be applied by applying an appropriate amount to the skin according to the skin area to be applied, and may be used once or several times per day as needed. The amount and frequency to be applied can be appropriately increased or decreased according to the necessity according to the skin condition of an individual, formulation, age, sex, weight, obesity, degree of symptom, reaction sensitivity, application period,
본 발명의 조성물을 의약으로서 투여하는 경우, 당업자는 목적하는 효과에 효과적인 투여량을 적절하게 선택할 수 있으며, 예를 들면, 유효량은 1일 피부 표면적(cm2) 당 0.1 mg 내지 5000 mg, 바람직하게는 100 mg 내지 500 mg 범위 내로서, 이를 1일 1 내지 5회 도포할 수 있다. 상기 조성물의 투여 제형은 단일투여 또는 반복투여 제형일 수 있으며, 상기 1일 유효량을 임의로 수회 나누어서 투여할 수 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다. When the composition of the present invention is administered as a medicament, a person skilled in the art can appropriately select an effective dose for the desired effect, for example, an effective amount is 0.1 mg to 5000 mg per one day of skin surface area (cm 2) Within the range of 100 mg to 500 mg, it may be applied 1 to 5 times a day. The dosage form of the composition may be a single dose or a repeated dosage form, and the effective daily dose may be administered in several divided doses. The dose is not intended to limit the scope of the invention in any way.
본 발명의 약학 또는 화장료 조성물은 유효성분의 투과력을 증진시키기 위한 목적으로, 이온토포레시스 (iontophoresis), 소노포레시스(sonophoresis), 전기천공법 (electroporation), 마이크로전자 패취(microelectric patch), 기계적 압력, 삼투압 구배, 차폐 요법(occlusive cure) 또는 미세주입요법, 또는 이들을 조합한 투여방법에 의해 피부에 적용될 수 있다.The pharmacological or cosmetic composition of the present invention may be used for the purpose of enhancing the permeability of an active ingredient, such as iontophoresis, sonophoresis, electroporation, microelectrical patch, The composition may be applied to the skin by means of pressure, osmotic gradient, occlusive cure or microinjection therapy, or a combination of these.
본 발명의 약학 또는 화장료 조성물은 단독의 요법으로 이용될 수 있으나, 운동 요법, 지방 흡입 수술, 호르몬 치료, 약물 치료, 식이요법 등과 병행하여 사용할 수 있다.The pharmaceutical or cosmetic composition of the present invention may be used as a sole therapy, but it can be used in combination with exercise therapy, liposuction, hormone therapy, medication, diet, and the like.
본 발명의 조성물은 유효성분의 피부 흡수율이 시간당 0.01 μg/cm2 내지 150 μg/cm2 이다. 바람직하게는 본 발명의 화장료 조성물은 피부 흡수율이 시간당 0.1 μg/cm2 내지 100 μg/cm2이며, 더욱 바람직하게는 시간당 1.0 μg/cm2 내지 50 μg/cm2이다. 피부 흡수율이 시간당 0.01 μg/cm2 미만인 경우 셀룰라이트 개선 효과가 미비하며, 피부 흡수율이 시간당 150 μg/cm2를 초과하는 경우 유효성분 투여량에 비하여 셀룰라이트 개선능/바디 슬리밍 효과의 증가 효과가 미비하여 경제적이지 못하다. In the composition of the present invention, the skin absorption rate of the active ingredient is 0.01 μg / cm 2 to 150 μg / cm 2 per hour. Preferably, the skin absorption rate of the cosmetic composition of the present invention is 0.1 μg / cm 2 to 100 μg / cm 2 per hour, more preferably 1.0 μg / cm 2 to 50 μg / cm 2 per hour. When the skin absorption rate is less than 0.01 μg / cm 2 per hour, the cellulite improving effect is insufficient. When the skin absorption rate exceeds 150 μg / cm 2 per hour, the cellulite improving effect / body slimming effect is insufficient It is not economical.
본 조성물을 첨가할 수 있는 제품으로는, 예를 들어, 화장수, 스킨, 로션, 영양로션, 영양크림, 맛사지크림, 에센스, 팩 등과 같은 화장품류와 클렌징, 세안제, 비누, 트리트먼트, 미용액 등이 있다.Examples of products to which the present composition can be added include cosmetics such as lotion, skin, lotion, nutrition lotion, nutritional cream, massage cream, essence, pack, cleansing, cleanser, soap, have.
본 발명의 화장료는 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스로 이루어진 군에서 선택된 조성물을 포함한다.The cosmetic composition of the present invention comprises a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high molecular weight peptides, polymeric polysaccharides, sphingolipids and seaweed extracts.
수용성 비타민으로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 비타민 B1, 비타민 B2, 비타민 B6, 피리독신, 염산피리독신, 비타민 B12, 판토텐산, 니코틴산, 니코틴산아미드, 엽산, 비타민 C, 비타민 H 등을 들 수 있으며, 그들의 염 (티아민염산염, 아스코르빈산나트륨염 등)이나 유도체 (아스코르빈산-2-인산나트륨염, 아스코르빈산-2-인산마그네슘염 등)도 본 발명에서 사용할 수 있는 수용성 비타민에 포함된다. 수용성 비타민은 미생물 변환법, 미생물의 배양물로부터의 정제법, 효소법 또는 화학 합성법 등의 통상의 방법에 의해 수득할 수 있다.The water-soluble vitamin is not particularly limited as long as it can be compounded in cosmetics. Preferably, vitamin B, vitamin B2, vitamin B6, pyridoxine, pyridoxine hydrochloride, vitamin B12, pantothenic acid, nicotinic acid, nicotinic acid amide, folic acid, vitamin C, And their salts (thiamine hydrochloride, sodium ascorbate, etc.) or derivatives (sodium ascorbic acid-2-phosphate, magnesium ascorbate-2-phosphate etc.) can also be added to water-soluble vitamins . The water-soluble vitamin can be obtained by a conventional method such as a microorganism conversion method, a purification method from a culture of a microorganism, an enzymatic method, or a chemical synthesis method.
유용성 비타민으로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 비타민 A, 카로틴, 비타민 D2, 비타민 D3, 비타민 E (d1-알파 토코페롤, d-알파 토코페롤, d-알파 토코페롤) 등을 들 수 있으며, 그들의 유도체 (팔미틴산아스코르빈, 스테아르산아스코르빈, 디팔미틴산아스코르빈, 아세트산 dl-알파 토코페롤, 니코틴산 dl-알파 토코페롤비타민 E, dl-판토테닐알코올, D-판토테닐알코올, 판토테닐에틸에테르 등) 등도 본 발명에서 사용되는 유용성 비타민에 포함된다. 유용성 비타민은 미생물 변환법, 미생물의 배양물로부터의 정제법, 효소 또는 화학 합성법 등의 통상의 방법에 의해 취득할 수 있다.Usable vitamins include vitamins such as vitamin A, carotene, vitamin D2, vitamin D3, vitamin E (d1-alpha tocopherol, d-alpha tocopherol, d-alpha tocopherol) , Derivatives thereof (such as palmitic acid ascorbin, stearic acid ascorbic acid, dipalmitic acid ascorbin, dl-alpha tocopherol acetic acid, dl-alpha tocopherol nicotinic acid vitamin E, dl-pantothenyl alcohol, D-pantothenyl alcohol, Ether, etc.) are also included in the usable vitamins used in the present invention. Usability Vitamins can be obtained by a conventional method such as a microorganism conversion method, a purification method from a culture of a microorganism, an enzyme or a chemical synthesis method.
고분자 펩티드로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 콜라겐, 가수 분해 콜라겐, 젤라틴, 엘라스틴, 가수 분해 엘라스틴, 케라틴 등을 들 수 있다. 고분자 펩티드는 미생물의 배양액으로부터의 정제법, 효소법 또는 화학 합성법 등의 통상의 방법에 의해 정제 취득할 수 있으며, 또는 통상 돼지나 소 등의 진피, 누에의 견섬유 등의 천연물로부터 정제하여 사용할 수 있다.The polymeric peptide may be any compound as long as it can be compounded in cosmetics, and examples thereof include collagen, hydrolyzed collagen, gelatin, elastin, hydrolyzed elastin, and keratin. The polymeric peptide can be obtained by a conventional method such as purification from a culture broth of a microorganism, an enzymatic method, or a chemical synthesis method, or it can be purified from natural products such as ducks such as pigs and cows and silk fiber of silkworms.
고분자 다당으로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 히드록시에틸셀룰로오스, 크산탄검, 히알루론산나트륨, 콘드로이틴 황산 또는 그 염 (나트륨염 등) 등을 들 수 있다. 예를 들어, 콘드로이틴 황산 또는 그 염 등은 통상 포유동물이나 어류로부터 정제하여 사용할 수 있다.The polymeric polysaccharide may be any compound as long as it can be incorporated in cosmetics, and examples thereof include hydroxyethyl cellulose, xanthan gum, sodium hyaluronate, chondroitin sulfate or a salt thereof (sodium salt, etc.). For example, chondroitin sulfate or a salt thereof can be usually purified from mammals or fish.
스핑고 지질로서는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 세라미드, 피토스핑고신, 스핑고당지질 등을 들 수 있다. 스핑고 지질은 통상 포유류, 어류, 패류, 효모 또는 식물 등으로부터 통상의 방법에 의해 정제하거나 화학 합성법에 의해 취득할 수 있다.Sphingo lipids may be any as long as they can be incorporated into cosmetics, and preferable examples thereof include ceramides, phytosphingosine and sphingoglycolipids. Sphingoid lipids can be purified from ordinary mammals, fish, shellfish, yeast or plants by conventional methods or can be obtained by chemical synthesis.
해초 엑기스로는 화장품에 배합 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 갈조 엑기스, 홍조 엑기스, 녹조 엑기스 등을 들 수 있으며, 또, 이들의 해초 엑기스로부터 정제된 칼라기난, 아르긴산, 아르긴산나트륨, 아르긴산칼륨 등도 본 발명에서 사용되는 해초 엑기스에 포함된다. 해초 엑기스는 해초로부터 통상의 방법에 의해 정제하여 취득할 수 있다.The seaweed extract may be any of those which can be compounded in cosmetics. Preferably, the seaweed extract is selected from the group consisting of algae extract, red pepper extract, green algae extract and the like. Also, the algae extract may be colored guanine, arginic acid, Potassium alginate and the like are also included in the seaweed extract used in the present invention. Seaweed extract can be obtained from seaweed by a conventional method.
본 발명의 화장료에는 상기 필수 성분과 더불어 필요에 따라 통상 화장료에 배합되는 다른 성분을 배합해도 된다.The cosmetic of the present invention may be blended with other essential ingredients, if necessary, in combination with the essential ingredients.
이외에 첨가해도 되는 배합 성분으로서는 유지 성분, 보습제, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 들 수 있다.Examples of the compounding ingredients that may be added include organic solvents such as a preservative component, a moisturizer, an emollient, a surfactant, an organic and inorganic pigment, an organic powder, an ultraviolet absorbent, a preservative, a bactericide, an antioxidant, a plant extract, a pH adjuster, A blood circulation accelerator, a cold agent, an antiperspirant agent, and purified water.
유지 성분으로서는 에스테르계 유지, 탄화수소계 유지, 실리콘계 유지, 불소계 유지, 동물 유지, 식물 유지 등을 들 수 있다.Examples of the oil retaining component include ester-based oil retaining, hydrocarbon-based oil retaining, silicone-based oil retaining, fluoric oil retaining, animal retention and plant retention.
에스테르계 유지로서는 트리2-에틸헥산산글리세릴, 2-에틸헥산산세틸, 미리스틴산이소프로필, 미리스틴산부틸, 팔미틴산이소프로필, 스테아르산에틸, 팔미틴산옥틸, 이소스테아르산이소세틸, 스테아르산부틸, 리놀레산에틸, 리놀레산이소프로필, 올레인산에틸, 미리스틴산이소세틸, 미리스틴산이소스테아릴, 팔미틴산이소스테아릴, 미리스틴산옥틸도데실, 이소스테아르산이소세틸, 세바신산디에틸, 아디핀산디이소프로필, 네오펜탄산이소알킬, 트리(카프릴, 카프린산)글리세릴, 트리2-에틸헥산산트리메틸롤프로판, 트리이소스테아르산트리메틸롤프로판, 테트라2-에틸헥산산펜타엘리슬리톨, 카프릴산세틸, 라우린산데실, 라우린산헥실, 미리스틴산데실, 미리스틴산미리스틸, 미리스틴산세틸, 스테아르산스테아릴, 올레인산데실, 리시노올레인산세틸, 라우린산이소스테아릴, 미리스틴산이소트리데실, 팔미틴산이소세틸, 스테아르산옥틸, 스테아르산이소세틸, 올레인산이소데실, 올레인산옥틸도데실, 리놀레산옥틸도데실, 이소스테아르산이소프로필, 2-에틸헥산산세토스테아릴, 2-에틸헥산산스테아릴, 이소스테아르산헥실, 디옥탄산에틸렌글리콜, 디올레인산에틸렌글리콜, 디카프린산프로필렌글리콜, 디(카프릴,카프린산)프로필렌글리콜, 디카프릴산프로필렌글리콜, 디카프린산네오펜틸글리콜, 디옥탄산네오펜틸글리콜, 트리카프릴산글리세릴, 트리운데실산글리세릴, 트리이소팔미틴산글리세릴, 트리이소스테아르산글리세릴, 네오펜탄산옥틸도데실, 옥탄산이소스테아릴, 이소노난산옥틸, 네오데칸산헥실데실, 네오데칸산옥틸도데실, 이소스테아르산이소세틸, 이소스테아르산이소스테아릴, 이소스테아르산옥틸데실, 폴리글리세린올레인산에스테르, 폴리글리세린이소스테아르산에스테르, 시트르산트리이소세틸, 시트르산트리이소알킬, 시트르산트리이소옥틸, 락트산라우릴, 락트산미리스틸, 락트산세틸, 락트산옥틸데실, 시트르산트리에틸, 시트르산아세틸트리에틸, 시트르산아세틸트리부틸, 시트르산트리옥틸, 말산디이소스테아릴, 히드록시스테아르산 2-에틸헥실, 숙신산디2-에틸헥실, 아디핀산디이소부틸, 세바신산디이소프로필, 세바신산디옥틸, 스테아르산콜레스테릴, 이소스테아르산콜레스테릴, 히드록시스테아르산콜레스테릴, 올레인산콜레스테릴, 올레인산디히드로콜레스테릴, 이소스테아르산피트스테릴, 올레인산피트스테릴, 12-스테알로일히드록시스테아르산이소세틸, 12-스테알로일히드록시스테아르산스테아릴, 12-스테알로일히드록시스테아르산이소스테아릴 등의 에스테르계 등을 들 수 있다.Examples of ester-based fats include glyceryl tri-2-ethylhexanoate, cetyl 2-ethylhexanoate, isopropyl myristate, butyl myristate, isopropyl palmitate, ethyl stearate, octyl palmitate, isostearyl isostearate, Butyl isopropyl myristate, isopropyl myristate, isopropyl myristate, isopropyl myristate, isopropyl myristate, isopropyl myristate, butyl, ethyl linoleate, isopropyl linoleate, ethyl oleate, isosilyl myristate, isostearic acid isostearyl, isostearyl palmitate, octyldodecyl myristate, Trimethylol propane, triisostearic acid trimethylol propane, tetra 2-ethylhexanoic acid pentaerythritol tetra (2-ethylhexanoate) , Decyl caprylate, decyl laurate, hexyl laurate, myristate decyl, myristyl myristate, myristine monoethyl stearate, stearyl stearate, decyl oleate, ricinoleic acid tri , Isostearyl stearate, isostearyl stearate, isodecyl stearate, octyldodecyl oleate, octyldodecyl linoleate, isopropyl isostearate, isopropyl stearate, isopropyl stearate, isopropyl stearate, -Hexyl stearate, stearyl ethylhexanoate, stearyl 2-ethylhexanoate, hexyl isostearate, ethylene glycol dioctanoate, ethylene glycol dioleate, propylene glycol dicaprate, di (capryl, capric acid) propylene glycol, Propyleneglycol propionate, propyleneglycol propionate, dicaproic acid neopentyl glycol, dioctanoic acid neopentyl glycol, tricarboxylic acid glyceryl, triunsaturated glyceryl, triisopalmitic acid glyceryl, triisostearic acid glyceryl, neopentanoic acid octyldodecyl Octanoic acid octanoate, octanoic acid octanoate, octanoic acid octanoate, octanoic acid octanoate, octanoic acid octanoate, octanoic acid octanoate, Octyldecyl lactate, octyldecyl lactate, octyldecyl lactate, polyglycerin oleic acid ester, polyglycerin isostearic acid ester, triisocetyl citrate, triisobutyl citrate, triisooctyl citrate, lauryl lactate, myristyl lactate, But are not limited to, ethyl, acetyltriethyl citrate, acetyltributyl citrate, trioctyl citrate, diisostearyl malate, 2-ethylhexyl hydroxystearate, di-2-ethylhexyl succinate, diisobutyl adipate, diisopropyl sebacate, But are not limited to, dioctyl sebacate, stearic acid cholesteryl, isostearic acid cholesteryl, hydroxystearic acid cholesteryl, oleic acid cholesteryl, oleic acid dihydrocholesteryl, isostearic acid pitostearyl, Stearoyl hydroxystearic acid isostearyl, 12-stearoyl stearyl hydroxystearate, 12-stearo And monohydroxystearic acid and esters such as sostearyl.
탄화 수소계 유지로서는 스쿠알렌, 유동 파라핀, 알파-올레핀올리고머, 이소파라핀, 세레신, 파라핀, 유동 이소파라핀, 폴리부덴, 마이크로크리스탈린왁스, 와셀린 등의 탄화 수소계 유지 등을 들 수 있다.Examples of the hydrocarbon hydrocarbon-based fats include hydrocarbon fats and oils such as squalene, liquid paraffin, alpha-olefin oligomer, isoparaffin, ceresin, paraffin, floating isoparaffin, polybutene, microcrystalline wax and vaseline.
실리콘계 유지로서는 폴리메틸실리콘, 메틸페닐실리콘, 메틸시클로폴리실록산, 옥타메틸폴리실록산, 데카메틸폴리실록산, 도데카메틸시클로실록산, 디메틸실록산ㆍ메틸세틸옥시실록산 공중합체, 디메틸실록산ㆍ메틸스테알록시실록산 공중합체, 알킬 변성 실리콘유, 아미노 변성 실리콘유 등을 들 수 있다.Examples of silicone based oils include polymethyl silicone, methylphenyl silicone, methyl cyclopolysiloxane, octamethylpolysiloxane, decamethylpolysiloxane, dodecamethylcyclosiloxane, dimethylsiloxane-methylcetyloxysiloxane copolymer, dimethylsiloxane-methylstarchoxysiloxane copolymer, alkyl Modified silicone oils, and amino-modified silicone oils.
불소계 유지로서는 퍼플루오로폴리에테르 등을 들 수 있다.Examples of the fluorine-based oil include perfluoropolyether and the like.
동물 또는 식물 유지로서는 아보카도유, 아르몬드유, 올리브유, 참깨유, 쌀겨유, 새플라워유, 대두유, 옥수수유, 유채유, 행인(杏仁)유, 팜핵유, 팜유, 피마자유, 해바라기유, 포도종자유, 면실유, 야자유, 쿠쿠이너트유, 소맥배아유, 쌀 배아유, 시아버터, 월견초유, 마커데이미아너트유, 메도홈유, 난황유, 우지(牛脂), 마유, 밍크유, 오렌지라피유, 호호바유, 캔데리러왁스, 카르나바왁스, 액상 라놀린, 경화피마자유 등의 동물 또는 식물 유지를 들 수 있다.Examples of animal or vegetable oils include avocado oil, almond oil, olive oil, sesame oil, rice bran oil, new flower oil, soybean oil, corn oil, rape oil, apricot kernel oil, palm kernel oil, palm oil, castor oil, , Corn oil, palm oil, palm oil, cucumber nut oil, wheat germ oil, rice germ oil, shea butter, coltsfoot colostrum, marker daisy nut oil, mead home oil, egg oil, , Canned wax, carnauba wax, liquid lanolin, hardened castor oil, and the like.
보습제로서는 수용성 저분자 보습제, 지용성 분자 보습제, 수용성 고분자, 지용성 고분자 등을 들 수 있다.Examples of the moisturizing agent include water-soluble low-molecular moisturizing agents, oil-soluble molecular moisturizing agents, water-soluble polymers, and oil-soluble polymers.
수용성 저분자 보습제로서는 세린, 글루타민, 솔비톨, 만니톨, 피롤리돈-카르복실산나트륨, 글리세린, 프로필렌글리콜, 1,3-부틸렌글리콜, 에틸렌글리콜, 폴리에틸렌글리콜B(중합도 n = 2 이상), 폴리프로필렌글리콜(중합도 n = 2 이상), 폴리글리세린B(중합도 n = 2 이상), 락트산, 락트산염 등을 들 수 있다.Examples of the water-soluble low-molecular moisturizing agent include serine, glutamine, sorbitol, mannitol, sodium pyrrolidone-carboxylate, glycerin, propylene glycol, 1,3-butylene glycol, ethylene glycol, polyethylene glycol B Glycol (polymerization degree n = 2 or more), polyglycerin B (polymerization degree n = 2 or more), lactic acid, lactic acid salt and the like.
지용성 저분자 보습제로서는 콜레스테롤, 콜레스테롤에스테르 등을 들 수 있다.Examples of the lipid-soluble low-molecular moisturizing agent include cholesterol and cholesterol ester.
수용성 고분자로서는 카르복시비닐폴리머, 폴리아스파라긴산염, 트라가칸트, 크산탄검, 메틸셀룰로오스, 히드록시메틸셀룰로오스, 히드록시에틸셀룰로오스, 히드록시프로필셀룰로오스, 카르복시메틸셀룰로오스, 수용성 키틴, 키토산, 덱스트린 등을 들 수 있다.Examples of the water-soluble polymer include carboxyvinyl polymer, polyaspartic acid, tragacanth, xanthan gum, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, water-soluble chitin, chitosan, dextrin, etc. .
지용성 고분자로서는 폴리비닐피롤리돈ㆍ에이코센 공중합체, 폴리비닐피롤리돈ㆍ헥사데센 공중합체, 니트로셀룰로오스, 덱스트린지방산에스테르, 고분자 실리콘 등을 들 수 있다.Examples of the oil-soluble polymer include polyvinylpyrrolidone / eicosene copolymer, polyvinylpyrrolidone / hexadecene copolymer, nitrocellulose, dextrin fatty acid ester, and polymer silicone.
에몰리엔트제로서는 장쇄아실글루타민산콜레스테릴에스테르, 히드록시스테아르산콜레스테릴, 12-히드록시스테아르산, 스테아르산, 로진산, 라놀린지방산콜레스테릴에스테르 등을 들 수 있다.Examples of the emollients include long chain acyl glutamic acid cholesteryl ester, hydroxystearic acid cholesteryl, 12-hydroxystearic acid, stearic acid, rosin acid and lanolin fatty acid cholesteryl ester.
계면 활성제로서는 비이온성 계면 활성제, 음이온성 계면 활성제, 양이온성 계면 활성제, 양성 계면 활성제 등을 들 수 있다.Examples of the surfactant include nonionic surfactants, anionic surfactants, cationic surfactants, and amphoteric surfactants.
비이온성 계면 활성제로서는 자기 유화형 모노스테아르산글리세린, 프로필렌글리콜지방산에스테르, 글리세린지방산에스테르, 폴리글리세린지방산에스테르, 솔비탄지방산에스테르, POE (폴리옥시에틸렌)솔비탄지방산에스테르, POE 솔비트지방산에스테르, POE 글리세린지방산에스테르, POE 알킬에테르, POE 지방산에스테르, POE 경화피마자유, POE 피마자유, POEㆍPOP (폴리옥시에틸렌ㆍ폴리옥시프로필렌) 공중합체, POEㆍPOP 알킬에테르, 폴리에테르변성실리콘, 라우린산알카놀아미드, 알킬아민옥시드, 수소첨가대두인지질 등을 들 수 있다.Examples of the nonionic surfactant include self emulsifying monostearate glycerin, propylene glycol fatty acid ester, glycerin fatty acid ester, polyglycerin fatty acid ester, sorbitan fatty acid ester, POE (polyoxyethylene) sorbitan fatty acid ester, POE sorbit fatty acid ester, POE (Polyoxyethylene / polyoxypropylene) copolymer, POE.POP alkyl ether, polyether-modified silicone, polyether-modified silicone, polyoxyethylene-polyoxypropylene (POE) Alkanolamides, alkylamine oxides, hydrogenated soybean phospholipids, and the like.
음이온성 계면 활성제로서는 지방산비누, 알파-아실술폰산염, 알킬술폰산염, 알킬알릴술폰산염, 알킬나프탈렌술폰산염, 알킬황산염, POE 알킬에테르황산염, 알킬아미드황산염, 알킬인산염, POE 알킬인삼염, 알킬아미드인산염, 알킬로일알킬타우린염, N-아실아미노산염, POE 알킬에테르카르복실산염, 알킬술포숙신산염, 알킬술포아세트산나트륨, 아실화 가수분해 콜라겐펩티드염, 퍼플루오로알킬인산에스테르 등을 들 수 있다.Examples of the anionic surfactant include fatty acid soap, alpha-acylsulfonate, alkylsulfonate, alkylarylsulfonate, alkylnaphthalenesulfonate, alkylsulfate, POE alkyl ether sulfate, alkylamide sulfate, alkyl phosphate, POE alkyl ginseng salt, Alkylsulfosuccinic acid salts, acylated hydrolyzed collagen peptide salts, and perfluoroalkyl phosphoric acid esters, and the like can be mentioned. have.
양이온성 계면 활성제로서는 염화알킬트리메틸암모늄, 염화스테아릴트리메틸암모늄, 브롬화스테아릴트리메틸암모늄, 염화세토스테아릴트리메틸암모늄, 염화디스테아릴디메틸암모늄, 염화스테아릴디메틸벤질암모늄, 브롬화베헤닐트리메틸암모늄, 염화벤잘코늄, 스테아르산디에틸아미노에틸아미드, 스테아르산디메틸아미노프로필아미드, 라놀린 유도체 제 4급 암모늄염 등을 들 수 있다.Examples of the cationic surfactant include alkyl trimethyl ammonium chloride, stearyl trimethyl ammonium chloride, stearyl trimethyl ammonium bromide, cetostearyl trimethyl ammonium chloride, distearyl dimethyl ammonium chloride, stearyl dimethyl benzyl ammonium chloride, behenyl trimethyl ammonium chloride, Benzalkonium, diethylaminoethylamide stearate, dimethylaminopropylamide stearate, quaternary ammonium salts of lanolin derivatives, and the like.
양성 계면 활성제로서는 카르복시베타인형, 아미드베타인형, 술포베타인형, 히드록시술포베타인형, 아미드술포베타인형, 포스포베타인형, 아미노카르복실산염형, 이미다졸린 유도체형, 아미드아민형 등의 양성 계면 활성제 등을 들 수 있다.Examples of the amphoteric surfactant include carboxybetaine type, amide betaine type, sulfobetaine type, hydroxysulfobetaine type, amidosulfobetaine type, phosphobetaine type, aminocarboxylate type, imidazoline derivative type and amide amine type Amphoteric surfactants and the like.
유기 및 무기 안료로서는 규산, 무수규산, 규산마그네슘, 탤크, 세리사이트, 마이카, 카올린, 벵갈라, 클레이, 벤토나이트, 티탄피막운모, 옥시염화비스무트, 산화지르코늄, 산화마그네슘, 산화아연, 산화티탄, 산화알루미늄, 황산칼슘, 황산바륨, 황산마그네슘, 탄산칼슘, 탄산마그네슘, 산화철, 군청, 산화크롬, 수산화크롬, 칼라민 및 이들의 복합체등의 무기 안료 ; 폴리아미드, 폴리에스테르, 폴리프로필렌, 폴리스티렌, 폴리우레탄, 비닐수지, 요소수지, 페놀수지, 불소수지, 규소수지, 아크릴수지, 멜라민수지, 에폭시수지, 폴리카보네이트수지, 디비닐벤젠ㆍ스티렌 공중합체, 실크파우더, 셀룰로오스, CI 피그먼트옐로우, CI 피그먼트오렌지 등의 유기 안료 및 이들의 무기 안료와 유기 안료의 복합 안료 등을 들 수 있다.Examples of the organic and inorganic pigments include inorganic pigments such as silicic acid, silicic anhydride, magnesium silicate, talc, sericite, mica, kaolin, Bengala, clay, bentonite, titanium mica, titanium oxide, bismuth chloride, zirconium oxide, magnesium oxide, Inorganic pigments such as calcium sulfate, barium sulfate, magnesium sulfate, calcium carbonate, magnesium carbonate, iron oxide, chromium oxide, chromium oxide, chromium hydroxide, But are not limited to, polyamide, polyester, polypropylene, polystyrene, polyurethane, vinyl resin, urea resin, phenol resin, fluororesin, silicon resin, acrylic resin, melamine resin, epoxy resin, polycarbonate resin, Silk powder, cellulose, CI Pigment Yellow, CI Pigment Orange, and composite pigments of inorganic pigments and organic pigments thereof.
유기 분체로서는 스테아르산칼슘 등의 금속비누 ; 세틸린산아연나트륨, 라우릴린산아연, 라우릴린산칼슘 등의 알킬인산금속염 ; N-라우로일-베타-알라닌칼슘, N-라우로일-베타-알라닌아연, N-라우로일글리신칼슘 등의 아실아미노산 다가금속염 ; N-라우로일-타우린칼슘, N-팔미토일-타우린칼슘 등의 아미드술폰산 다가금속염 ; N-엡실론-라우로일-L-리진, N-엡실론-팔미토일리진, N-알파-파리토일올니틴, N-알파-라우로일아르기닌, N-알파-경화우지지방산아실아르기닌 등의 N-아실염기성아미노산 ; N-라우로일글리실글리신 등의 N-아실폴리펩티드 ; 알파-아미노카프릴산, 알파-아미노라우린산 등의 알파-아미노지방산 ; 폴리에틸렌, 폴리프로필렌, 나일론, 폴리메틸메타크릴레이트, 폴리스티렌, 디비닐벤젠ㆍ스티렌 공중합체, 사불화에틸렌 등을 들 수 있다.As the organic powder, metallic soap such as calcium stearate; Metal salts of alkyl phosphates such as sodium zinc cetylate, zinc laurylate and calcium lauryl laurate; Acylamino acid polyvalent metal salts such as N-lauroyl-beta-alanine calcium, N-lauroyl-beta-alanine zinc and N-lauroylglycine calcium; Amidosulfonic acid multivalent metal salts such as N-lauroyl-taurine calcium and N-palmitoyl-taurine calcium; Such as N-epsilon-lauroyl-L-lysine, N-epsilon-palmitoylidene, N-alpha-paratyylnitine, N-alpha-lauroyl arginine, Acyl basic amino acids; N-acylpolypeptides such as N-lauroylglycylglycine; Alpha-amino fatty acids such as alpha-aminocaprylic acid, alpha-aminoaurauric acid, and the like; Polyethylene, polypropylene, nylon, polymethylmethacrylate, polystyrene, divinylbenzene-styrene copolymer, ethylene tetrafluoride, and the like.
자외선 흡수제로서는 파라아미노벤조산, 파라아미노벤조산에틸, 파라아미노벤조산아밀, 파라아미노벤조산옥틸, 살리실산에틸렌글리콜, 살리신산페닐, 살리신산옥틸, 살리신산벤질, 살리신산부틸페닐, 살리신산호모멘틸, 계피산벤질, 파라메톡시계피산-2-에톡시에틸, 파라메톡시계피산옥틸, 디파라메톡시계피산모노-2-에틸헥산글리세릴, 파라메톡시계피산이소프로필, 디이소프로필ㆍ디이소프로필계피산에스테르 혼합물, 우로카닌산, 우로카닌산에틸, 히드록시메톡시벤조페논, 히드록시메톡시벤조페논술폰산 및 그 염, 디히드록시메톡시벤조페논, 디히드록시메톡시벤조페논디술폰산나트륨, 디히드록시벤조페논, 테트라히드록시벤조페논, 4-tert-부틸-4'-메톡시디벤조일메탄, 2,4,6-트리아닐리노-p-(카르보-2'-에틸헥실-1'-옥시)-1,3,5-트리아진, 2-(2-히드록시-5-메틸페닐)벤조트리아졸 등을 들 수 있다.Examples of ultraviolet absorbers include paraaminobenzoic acid, ethyl parnamobenzoate, amyl paranobenzoate, octyl paranobenzoate, ethyleneglycol salicylate, phenyl salicylate, benzyl salicylate, benzyl salicylate, butylphenyl salicylate, homomenthyl salicylate, benzyl cinnamate , Octyl methoxycinnamate, dioctyl methoxycinnamate, mono-2-ethylhexane glyceryl dipyrromethoxycinnamate, isopropyl paratumoxycinnamate, diisopropyl-diisopropyl cinnamate ester mixture, Carninoic acid, ethyl urocanoate, hydroxymethoxybenzophenone, hydroxymethoxybenzophenone sulfonic acid and salts thereof, dihydroxymethoxybenzophenone, sodium dihydroxymethoxybenzophenone disulfonate, dihydroxybenzophenone , Tetrahydroxybenzophenone, 4- tert -butyl-4'-methoxydibenzoylmethane, 2,4,6-trianylino- p- (carbo-2'-ethylhexyl-1'- , 3,5-triazine, 2- (2- And the like can be mentioned hydroxy-5-methylphenyl) benzotriazole.
살균제로서는 히노키티올, 트리클로산, 트리클로로히드록시디페닐에테르, 크로르헥시딘글루콘산염, 페녹시에탄올, 레조르신, 이소프로필메틸페놀, 아줄렌, 살리칠산, 진크필리티온, 염화벤잘코늄, 감광소 301 호, 모노니트로과이어콜나트륨, 운데시렌산 등을 들 수 있다.Examples of the disinfectant include hinokitiol, trichloroacid, trichlorohydroxydiphenyl ether, crohexidine gluconate, phenoxyethanol, resorcin, isopropylmethylphenol, azulene, salicylic acid, zinc filitione, benzalkonium chloride, No. 301, mononitro and eicol sodium, and undecylenic acid.
산화 방지제로서는 부틸히드록시아니솔, 갈릭산프로필, 엘리소르빈산 등을 들 수 있다.Examples of the antioxidant include butylhydroxyanisole, gallic acid propyl, and eicosorbic acid.
pH 조정제로서는 시트르산, 시트르산나트륨, 말산, 말산나트륨, 프말산, 프말산나트륨, 숙신산, 숙신산나트륨, 수산화나트륨, 인산일수소나트륨 등을 들 수 있다.Examples of the pH adjuster include citric acid, sodium citrate, malic acid, sodium malate, fumaric acid, sodium fumarate, succinic acid, sodium succinate, sodium hydroxide, sodium monohydrogenphosphate and the like.
알코올로서는 세틸알코올 등의 고급 알코올을 들 수 있다.Examples of the alcohol include higher alcohols such as cetyl alcohol.
또한, 이외에 첨가해도 되는 배합 성분은 이에 한정되는 것은 아니며, 또, 상기 어느 성분도 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 배합 가능하지만, 총중량에 대하여 바람직하게는 0.01 - 5 % 중량, 보다 바람직하게는 0.01 - 3 % 중량로 배합된다.In addition, any of the above components may be blended within the range not to impair the objects and effects of the present invention, but it is preferably 0.01 to 5% by weight based on the total weight, Preferably 0.01 to 3% by weight.
본 발명의 화장료는 용액, 유화물, 점성형 혼합물 등의 형상을 취할 수 있다.The cosmetic of the present invention may take the form of a solution, an emulsion, a viscous mixture or the like.
본 발명의 화장료 조성물에 포함되는 성분은 유효성분으로서 상기 바이오셀룰로오스 분말 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예를 들면, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제 및 담체를 포함한다.The components contained in the cosmetic composition of the present invention may contain, as an active ingredient, the components commonly used in cosmetic compositions in addition to the above-mentioned bio-cellulose powders. For example, conventional ingredients such as stabilizers, solubilizers, vitamins, Phosphorus auxiliaries and carriers.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어 유액, 크림, 화장수, 팩, 파운데이션, 로션, 미용액, 모발화장료 등을 들 수 있다.The cosmetic composition of the present invention can be prepared into any formulation conventionally produced in the art, and examples thereof include emulsions, creams, lotions, packs, foundations, lotions, essences, and hair cosmetics.
구체적으로, 본 발명의 화장료 조성물은 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저의 제형을 포함한다.Specifically, the cosmetic composition of the present invention can be used as a skin lotion, a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nutrition lotion, a massage cream, a nutrition cream, a moisturizing cream, a hand cream, Packs, soaps, cleansing foams, cleansing lotions, cleansing creams, body lotions and body cleansers.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal fiber, plant fiber, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.In the case of the solution or emulsion of the present invention, a solvent, a solvent or an emulsifier is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolenic derivatives or ethoxylated glycerol fatty acid esters.
본 발명의 바이오셀룰로오스 분말을 사용한 모든 피험자를 대상으로 한 안티셀룰라이트 효과실험을 통하여 진피와 피하지방 경계면 두께를 유의하게 감소시키고 제품 사용 전과 비교시 제품 사용 후 대퇴부의 탄력성이 유의하게 개선되었으며(실험예 1); 피험자에 의한 유효성 설문조사(Global Assessment of Efficacy by Patient)에서 시험제품 사용 후 피험자가 느끼는 셀룰라이트 감소 정도 실험에서도 유의적인 셀룰라이트 제거 및 피부 탄력성 개선 효과를 나타내므로(실험예 2), 피부결을 매끄럽게 가꾸고 처짐을 방지하기 위한 미용 용도로서도 사용가능함을 확인하여 셀룰라이트 감소 및 예방용 피부외용 약학조성물 및 화장료 조성물로 유용하게 이용될 수 있다.The anti-cellulite effect test on all subjects using the bio-cellulose powder of the present invention significantly reduced the dermal and subcutaneous fat interface thickness and significantly improved the elasticity of the thigh after use of the product compared to before use Example 1); In the Global Assessment of Efficacy by Patient, the subject's cellulite reduction test after the use of the test product showed significant cellulite removal and skin elasticity improvement (Experimental Example 2) It can be used as a cosmetic application for preventing smoothing and sagging. Therefore, it can be usefully used as an external dermatological pharmaceutical composition and a cosmetic composition for reducing and preventing cellulite.
이하, 본 발명을 하기의 실시예 및 실험예에 의해 상세히 설명한다.Below, The present invention will be described in detail by the following examples and experimental examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 의해 한정되는 것은 아니다.However, the following examples and experimental examples are illustrative of the present invention, and the content of the present invention is not limited by the following examples and experimental examples.
실시예 1. 바이오셀룰로오스의 분말의 제조Example 1. Preparation of Powder of Bio-Cellulose
본 발명의 바이오셀룰로오스는 미생물 셀룰로오스에 과당 및 수분을 첨가하여 제조할 수 있는데, 미생물 셀룰로오스를 제조하기 위하여 코코넛수를 생수에 35%(v/v)가 되도록 희석하여 초산 1%(v/v)를 가한 배지(pH 3-4) 400 ㎖를 1L 삼각플라스크에 넣고, 아세토박터 균주(Acetobacter xylinum)를 접종하여 30℃, 150rpm 조건에서 1일 내지 3일간 진탕 시킨 후, 제조된 배양액 초모를 초산 1%(v/v)와 설탕 10%(v/v)가 포함된 35% 코코넛수 희석액(pH 3-4) 400㎖가 들어 있는 1L 비이커에 5%(v/v)로 접종하고, 30℃에서 5-8일간 정치배양하였다.The bio-cellulose of the present invention can be prepared by adding fructose and water to the micro-organism cellulose. To prepare micro-organism cellulose, coconut water is diluted to 35% (v / v) (Acetobacter xylinum) was inoculated in a 1 L Erlenmeyer flask, and the mixture was shaken at 30 DEG C and 150 rpm for 1 day to 3 days. Then, 35% containing 10% (v / v) and 10% (v / v) Was inoculated in a 1-liter beaker containing 400 ml of a coconut water dilution (pH 3-4) at 5% (v / v), and cultured at 30 ° C for 5 to 8 days.
상기의 과정을 통하여 제조된 5 - 8㎜ 두께의 반투명 겔 상의 미생물 셀룰로오스는 그 내부에 배지 성분 및 균체를 함유하고 있으므로, 물에 1-2일간 침지하고 맑은 물로 1-2회 세정한 후 100℃에서 20-60 분간 가열하여 불순물을 제거한다. 불순물이 제거된 겔 상의 미생물 셀룰로오스는 공압 압착기에서 스폰지를 이용하여 두께 약 0.4 - 0.8mm 정도로 압착하여 수분 함량이 85 - 95%의 미생물 셀룰로오스 웨트 시이트(wet sheet)를 제조하고, 제조된 웨트 시이트는 3% - 10% 과당 용액에 60 - 120분간 침지시킨다. 침지 후, 미생물 셀룰로오스는 과당액을 재 흡수하여 두께 2 - 4mm로 복원된다. 복원된 미생물 셀룰로오스를 공압 압착기로 재차 압착하면 두께 약 0.4 - 0.8mm인 바이오셀룰로오스 웨트 시이트가 제조된다.The 5 to 8 mm-thick semi-transparent gelatinous microbial cellulose prepared through the above process contains the medium components and the microbial cells therein. Therefore, it is immersed in water for 1-2 days, cleaned 1-2 times with clear water, For 20-60 minutes to remove impurities. The gel-like microbial cellulose with impurities removed is compressed in a pneumatic press using a sponge to a thickness of about 0.4-0.8 mm to produce a micro-cellulosic cellulose wet sheet having a moisture content of 85-95% Immerse in 3% - 10% fructose solution for 60 - 120 minutes. After immersion, the microbial cellulose reabsorbs the fructose solution and is restored to a thickness of 2-4 mm. The recovered microbial cellulose is compressed again with a pneumatic press to produce a biocellulose wet sheet having a thickness of about 0.4 to 0.8 mm.
제조된 바이오셀룰로오스 웨트 시이트는 50 - 80 ℃ 건조실에서 12 - 24 시간 건조시키고, 건조된 시이트를 건식 분쇄기로 분쇄하여 30 - 50 메시(mesh) 체에 통과시켜 바이오셀룰로오스 분말(이하, BC라 함)을 제조하였다.The prepared bio-cellulose wet sheet was dried in a drying chamber at 50 to 80 ° C. for 12 to 24 hours. The dried sheet was pulverized by a dry pulverizer and passed through a 30-50 mesh sieve to obtain a bio-cellulose powder (hereinafter referred to as BC) .
상기의 과정을 통하여 제조된 바이오셀룰로오스의 조성은 표 1과 같으며, 본 바이오셀룰로오스는 하기의 임상예의 시료로 사용하였다.The composition of the bio-cellulose prepared through the above procedure is shown in Table 1, and this bio-cellulose was used as a sample of the following clinical example.
실시예 2. 바이오셀룰로오스 분말 함유 조성물 제조Example 2. Preparation of composition containing bio-cellulose powder
실시예 1의 바이오셀룰로오스를 0.01 내지 10%에 정제수(수상 용제) 및 아크릴레이트(점증제)를 첨가하고 65~70℃ 가온 용해하였다. 상기 용해물을 냉각하고 약 50℃에서 에탄올(유상 용제)를 첨가하고 45℃에서 트리에탄올아민(중화제)로 중화한 다음 약 2,000rpm으로 5~10분간 유화시켰다. 그 후 나머지 구성성분을 넣어 약 3,300rpm으로 10분간 교반하여 최종 35℃로 냉각시켜 200mesh로 여과하여 표 2의 바이오셀룰로오스 분말 함유 조성물(이하, BCC라 함)을 제조하였다.Purified water (water-soluble solvent) and acrylate (thickener) were added to 0.01 to 10% of the bio-cellulose of Example 1 and dissolved at a temperature of 65 to 70 ° C. The lysate was cooled, and ethanol (oily solvent) was added at about 50 ° C, neutralized with triethanolamine (neutralizing agent) at 45 ° C, and emulsified at about 2,000 rpm for 5 to 10 minutes. Then, the remaining components were added, and the mixture was stirred at about 3,300 rpm for 10 minutes. The mixture was cooled to 35 DEG C and filtered at 200 mesh to prepare a composition containing a bio-cellulose powder (hereinafter referred to as BCC).
실험예Experimental Example 1. 임상시험 평가- 대퇴부에 대한 1. Evaluation of Clinical Trials - 슬리밍Slimming 효과 평가 Effect evaluation
본 시험에서는 병력 조사 및 피부 상태 진단을 통해 시험 목적에 적합한, 대퇴부 국소 비만 및 셀룰라이트가 있는 21~45세 (평균 연령 31.0세)의 여성 피험자 20명을 선정하였다 (Method of testing primary irritant substances 38(187): pp 1500-1541). In this study, 20 female subjects aged 21 to 45 years (mean age 31.0 years) with femoral topical obesity and cellulite were selected through a history examination and skin condition diagnosis (Method of testing primary irritant substances 38 (187): pp 1500-1541).
시험 제품은 상기 실시예 2에 따라 제조된 BCC 제형을 사용하였다.The test product used was the BCC formulation prepared according to Example 2 above.
피험자로 하여금 시험 제품을 4주 동안 1일 1회(저녁) 대퇴부에 도포하도록 하였다. 제품 사용 전 (0주), 제품 사용 2주 및 4주 후 시점에 대퇴부의 진피와 피하지방 경계면의 길이를 측정하여 피하지방 감소량을 평가하였다. 또한 검사관들에 의한 육안 평가에 의해 셀룰라이트 제거 및 탄력 개선 효과를 평가하였으며, 피험자들을 대상으로 피부처짐, 매끄러움 항목에 대한 설문 평가를 실시하였다.The subjects were allowed to apply the test article to the thighs once a day (evening) for four weeks. The amount of hypodermic fat reduction was evaluated by measuring the length of the dermis and subcutaneous fat interface between the thighs before the use (0 weeks), 2 weeks and 4 weeks after using the product. In addition, the cellulite removal and elasticity improvement effect was evaluated by the visual inspection by the inspectors, and the questionnaires of skin deflection and smoothness items were evaluated.
1-1. 실험 방법1-1. Experimental Method
초음파 촬영장치인 Dermascan C를 이용하여 무릎을 기준으로 15 cm 위의 대퇴부에서 진피와 피하지방의 경계면의 두께를 측정하였다. 측정은 제품 사용 전, 제품 사용 2주 및 4주 후 시점에 이루어졌으며, 최초 측정시의 위치가 표시된 투명 필름(transparent sheet)을 이용하여 동일한 부위를 측정 후 대조 분석하였다. 각각의 시점에 10명의 피험자들로부터 얻어진 측정치(단위:mm)의 평균값을 사용하였으며, Student t-test를 이용한 양측검정으로 사용 전과 후를 비교하여 통계적인 유의성을 분석하였다(유의 수준: p=0.05). 분석한 결과를 하기 표 3에 나타내었다.The thickness of the interface between the dermis and the subcutaneous fat was measured at 15 cm above the knee using a Dermascan C ultrasound system. Measurements were made before use, at 2 weeks and 4 weeks after use of the product, and the same area was measured using a transparent sheet showing the position at the time of initial measurement, and then the control was analyzed. Statistical significance was assessed by comparing the mean values of the measurements (in mm) obtained from 10 subjects at each time point and before and after using the Student t-test on both sides (significance level: p = 0.05 ). The results of the analysis are shown in Table 3 below.
시험제품 사용 전, 사용 2주 후, 사용 4주 후에 측정한 대퇴부 셀룰라이트 층 변화를 분석한 결과, 시험제품을 사용한 대퇴부의 셀룰라이트 층 두께 측정값은 사용 전에 5913.05±1032.24 (μm), 사용 2주 후에 5368.13±1203.55(μm), 사용 4주 후에 5017.13±1190.28(μm), 로 시험제품 사용 전에 비해 사용 2주 후, 사용 4주 후에 감소한 것으로 나타났다.The cellulite layer thickness measurements of the femur before use, after 2 weeks of use, and after 4 weeks of use were analyzed and found to be 5913.05 ± 1032.24 (μm) before use, After 5 weeks, 5368.13 ± 1203.55 (μm) and 5017.13 ± 1190.28 (μm) after 4 weeks of use, respectively.
이러한 대퇴부 셀룰라이트 층 두께의 감소 경향을 명확하게 알기 위하여 사용 전후 평균차에 대하여 통계적 방법을 통해 유의성 여부를 검정하였다. 정규성 검정에 따라 모수적 방법인 Paired sample's T-test와 비모수적 방법인 Wilcoxon signed rank test에 의하여 검정한 결과, 시험제품 사용 전과 비교하여 사용 2주 후, 4주 후에서 모두 p<0.05로 통계적으로 유의한 차이를 발견할 수 있었다(표 3).In order to clearly understand the decreasing tendency of the thickness of the thigh cellulite layer, the significance of the difference between the mean and the mean was determined by a statistical method. Statistical analysis was performed using the Paired sample's T-test, a parametric method, and the Wilcoxon signed rank test, a non-parametric method. The results were statistically significant at 2 weeks and 4 weeks after use, Significant differences were found (Table 3).
1-One- 2.실험2. Experiment 결과 result
결국, 본 발명의 시험 제품의 적용 2주 경과시, 적용 전의 상태와 비교했을 때 상기 경계면 두께가 약 8.8% 감소했고, 4주 경과시 약 12 % 감소하여, 적용 시간이 길어짐에 따라 피하지방층이 분해된다는 것을 확인하였다.As a result, when the test product of the present invention was applied two weeks after the application, the thickness of the interface decreased by about 8.8% and decreased by about 12% after 4 weeks, .
+: p<0.05 by wilcoxon signed rank Test*: p < 0.05 by Paired samples ' T-Test
+: p < 0.05 by wilcoxon signed rank Test
또한 육안 평가 결과, 제품 사용 전과 비교시 제품 사용 4주 후 대퇴부의 탄력성이 유의하게 개선되었으며, 셀룰라이트가 유의하게 감소하는 경향을 보였다.The results of visual evaluation showed that the elasticity of the thighs was significantly improved and the cellulite decreased significantly after 4 weeks of using the product compared to before use.
실험예 2. 피험자에 의한 유효성 설문조사(Global Assessment of Efficacy by Patient)Experimental Example 2. Global Assessment of Efficacy by Patient
본 시험에서는 병력 조사 및 피부 상태 진단을 통해 시험 목적에 적합한, 대퇴부 국소 비만 및 셀룰라이트가 있는 21~45세 (평균 연령 31.0세)의 여성 피험자 20명을 선정하였다 (Method of testing primary irritant substances 38(187): pp 1500-1541). In this study, 20 female subjects aged 21 to 45 years (mean age 31.0 years) with femoral topical obesity and cellulite were selected through a history examination and skin condition diagnosis (Method of testing primary irritant substances 38 (187): pp 1500-1541).
시험 제품은 상기 실시예 2에 따라 제조된 제형을 사용하였다.The test product used was the formulation prepared according to Example 2 above.
상기 피험자를 대상으로 한 피험자에 의한 설문 평가에서는, 시험제품 사용 후 피험자가 느끼는 셀룰라이트 감소 정도에 대하여 4 점 (아주좋음), 3점 (좋음), 2점 (보통), 1점 (나쁨), 0점 (아주나쁨)의 5단계로 피험자가 본인이 답하도록 하였다. 연구자는 각 답변에 대한 피험자 수의 백분율을 구하여 시험제품의 효능여부를 판단하였다.(Very good), 3 points (good), 2 points (normal), 1 point (poor), and 1 point (poor) in the degree of cellulite reduction experienced by the testee after using the test product, , And 0 point (very bad). The researchers determined the efficacy of the test product by obtaining the percentage of the subjects for each answer.
시험제품 사용 후의 셀룰라이트 감소 정도에 관하여 실시한 설문값의 평균과 표준편차 및 각 답변에 대한 피험자 수의 백분율을 구하였다.The mean and standard deviation of the questionnaire values and the percentage of the subjects to each answer were obtained for the degree of cellulite reduction after using the test product.
상기 실험 결과, 상기 피험자 대부분 보통 이상의 답변을 하였으며 셀룰라이트 감소에 긍정적 평가를 하는 것으로 나타났다.(표 4)As a result of the above-mentioned experiment, most of the subjects gave more than average answers and positively evaluated cellulite reduction (Table 4).
본 발명의 조성물은 유의한 셀룰라이트 제거 및 피부 탄력성 개선 효과를 나타내므로, 피부결을 매끄럽게 가꾸고 처짐을 방지하기 위한 미용 용도로서도 사용될 수 있다.Since the composition of the present invention exhibits significant cellulite removal and skin elasticity-improving effects, it can also be used for cosmetic purposes to smooth skin texture and prevent sagging.
이하, 본 발명의 제형예로서 크림, 맛사지크림, 로션, 스킨로션, 에센스, 팩, 클렌징폼의 제형을 예시하고 있으나, 본 발명의 화장품 조성물을 포함하는 제형은 이에 한정되는 것은 아니다.Hereinafter, formulations of cream, massage cream, lotion, skin lotion, essence, pack, and cleansing foam are exemplified as the formulation examples of the present invention, but the formulations including the cosmetic composition of the present invention are not limited thereto.
제형예Formulation Example 1. 크림조성물 1. Cream composition
유상과 수상을 각각 75 ℃로 가열 혼합한 후 실온으로 냉각한다.The oil phase and water phase are heated to 75 ° C and cooled to room temperature.
제형예Formulation Example 2. 2. 맛사지크림Massage Cream 조성물 Composition
유상과 수상을 각각 75 ℃로 가열 용해 혼합한 후 실온으로 냉각한다.The oil phase and water phase are mixed by heating at 75 DEG C and then cooled to room temperature.
제형예Formulation Example 3. 로션 조성물 3. lotion composition
유상과 수상을 각각 75 ℃로 가열 혼합 유화한 후 실온으로 냉각한다.The oil phase and water phase are mixed and emulsified by heating at 75 ° C and then cooled to room temperature.
제형예Formulation Example 4. 스킨로션 조성물 4. Skin lotion composition
수상과 에탄올상을 각각 제조 혼합한 후 여과한다.The water phase and the ethanol phase are respectively prepared and mixed and then filtered.
제형예Formulation Example 5. 에센스 조성물 5. Essence composition
수상과 에탄올상을 각각 제조 혼합한 후 여과한다.The water phase and the ethanol phase are respectively prepared and mixed and then filtered.
제형예Formulation Example 6. 팩 조성물 6. Pack composition
수상과 에탄올상을 각각 분산 용해하여 혼합시킨 후 실온으로 냉각한다.The water phase and the ethanol phase are dispersively dissolved and mixed, and then cooled to room temperature.
제형예Formulation Example 7. 7. 클렌징폼Cleansing Foam 조성물 Composition
수상과 오일상을 각각 분산 용해하여 혼합 검화한 후 실온으로 냉각한다.The water phase and the oil phase are dispersed and dissolved, mixed and sieved, and then cooled to room temperature.
Claims (4)
상기 화장료 조성물은 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 스프레이, 팩 등과 같은 화장품류 뿐만 아니라, 비누, 클렌징폼, 클렌징 로션, 클렌징 크림, 바디 로션, 바디 크림, 바디 오일, 바디 세정제, 샴푸, 연고, 패취, 화장수, 스킨, 로션, 보디용, 또는 얼굴 마스크 용 팩의 제형임을 특징으로 하는 화장료 조성물.The method according to claim 1,
The cosmetic composition may be at least one selected from the group consisting of a skin lotion, a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nutrition lotion, a massage cream, a nutritional cream, a moisturizing cream, a hand cream, a foundation, Formulations of packs for soaps, cleansing foams, cleansing lotions, cleansing creams, body lotions, body creams, body oils, body cleansers, shampoos, ointments, patches, lotions, skins, lotions, / RTI >
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160048596A KR101814538B1 (en) | 2016-04-21 | 2016-04-21 | A cosmentic composition comprising the bio-cellulose powder for reducing and preventing cellulite |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160048596A KR101814538B1 (en) | 2016-04-21 | 2016-04-21 | A cosmentic composition comprising the bio-cellulose powder for reducing and preventing cellulite |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170120305A KR20170120305A (en) | 2017-10-31 |
KR101814538B1 true KR101814538B1 (en) | 2018-01-03 |
Family
ID=60301588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160048596A Expired - Fee Related KR101814538B1 (en) | 2016-04-21 | 2016-04-21 | A cosmentic composition comprising the bio-cellulose powder for reducing and preventing cellulite |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101814538B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190140871A (en) * | 2018-06-12 | 2019-12-20 | 에스케이바이오랜드 주식회사 | Use of bacterial cellulose gel with reversible sol-gel phase transition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100202441B1 (en) | 1996-10-30 | 1999-06-15 | 문세민 | Manufacturing process of microbial cellulose from fruit juice |
KR101385501B1 (en) | 2013-10-10 | 2014-04-15 | (주)이지코스텍 | Manufacturing method of cosmetic biocellulose sheet and cosmetic biocellulose sheet by using therof |
-
2016
- 2016-04-21 KR KR1020160048596A patent/KR101814538B1/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100202441B1 (en) | 1996-10-30 | 1999-06-15 | 문세민 | Manufacturing process of microbial cellulose from fruit juice |
KR101385501B1 (en) | 2013-10-10 | 2014-04-15 | (주)이지코스텍 | Manufacturing method of cosmetic biocellulose sheet and cosmetic biocellulose sheet by using therof |
Non-Patent Citations (1)
Title |
---|
Food Science and Biotechnology. 2006. Vol.15. No.1, pp.70-76.* |
Also Published As
Publication number | Publication date |
---|---|
KR20170120305A (en) | 2017-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101881954B1 (en) | Cosmetic composition containing gynostemma pentaphyllum leaf extract | |
KR101754463B1 (en) | COSMETIC COMPOSITIONS CONTAINING the plants extract of Cyperaceae AND PREPARING METHOD OF THE SAME | |
KR101800161B1 (en) | Wheat seed extract showing potent inhibiting effect on skin aging, the preparation thereof and the compostion comprising the same | |
KR101229045B1 (en) | Extracting method of nelumbo nucifera flower, leaf, stem, root, seed and cosmetic composition for anti-wrinkle containing extracts thereby | |
JP6706017B2 (en) | Stem cell function maintenance agent | |
KR100805386B1 (en) | Anti-aging composition containing oyster fruit extract | |
KR101996732B1 (en) | Cosmetic composition comprising concentrate of Omegiju fermented using magma seawater for improving wrinkles, elasticity or moisturizing the skin | |
JP2004107243A (en) | Wrinkle and / or sag improvement kit | |
KR101814538B1 (en) | A cosmentic composition comprising the bio-cellulose powder for reducing and preventing cellulite | |
KR101814537B1 (en) | A skin topical composition comprising the bio-cellulose powder for reducing and preventing cellulite | |
KR102284899B1 (en) | Cosmetic composition comprising mature peptides of Astragalus membranaceus for improving skin vitality | |
KR101550422B1 (en) | Cosmetic composition containing Indigo extract | |
KR20190098603A (en) | Cosmetic composition comprising microorganism femented produsts with moisturizing effects | |
KR100706285B1 (en) | External skin composition containing platinum extract having anti-wrinkle and improving activity | |
KR20050045428A (en) | Cosmetic composition comprising an extract of flowers of prunus mume sieb. having antioxidant activity | |
KR100714172B1 (en) | Cosmetic composition having the effect of inhibiting wrinkles and improving | |
KR101912097B1 (en) | Cosmetic composition comprising extract from curcuma and oenothera laciniata hill | |
KR101973111B1 (en) | Novel levan compositions and the compositions comprising the same | |
KR101764823B1 (en) | Cosmetic composition comprising curcuma extract | |
KR102234670B1 (en) | Cosmetic composition comprising squalene and snail egg extract for preventing and improving striae gravidarum | |
KR102370418B1 (en) | A functional cosmetic composition that prevents and improves atopic dermatitis containing a compound separated from the gojiberry extract as an active ingredient | |
KR20180023643A (en) | Cosmetic composition comprising Polygonatum odoratum extract with Immproved feeling of use and skin moisturizing effect | |
KR20120078245A (en) | A preparation method for pse extract of prunella vulgaris having antioxidative effect and the cosmetic composition comprising the same | |
KR20110107054A (en) | Cosmetic composition containing seaweed extract showing antimicrobial activity as an active ingredient | |
KR20160079979A (en) | Cosmetic composition comprising of abalone mucus for skin wrinkle improvement or skin whitening |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20160421 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20170413 Patent event code: PE09021S01D |
|
PG1501 | Laying open of application | ||
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20171226 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20171227 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20171227 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20211007 |